Targeting the Atypical Chemokine Receptor ACKR3/CXCR7 for the treatment of cancer and other diseases by NC DOCKS at The University of North Carolina at Greensboro & Vestal, Richard D.
 
 
VESTAL JR., RICHARD D., Ph.D. Targeting the Atypical Chemokine Receptor 
ACKR3/CXCR7 for the Treatment of Cancer and Other Diseases. (2015)             
Directed by Dr. Ethan W. Taylor. 108 pp. 
 
 
One of the greatest challenges in fighting cancer is cell targeting and biomarker 
selection.  The Atypical Chemokine Receptor ACKR3/CXCR7 is expressed on many 
cancer cell types, including breast cancer and glioblastoma, and binds the endogenous 
ligands SDF1/CXCL12 and ITAC/CXCL11. A 20 amino acid region of the 
ACKR3/CXCR7 N-terminus was synthesized and targeted with the NEB PhD™-7 Phage 
Display Peptide Library. Twenty-nine phages were isolated and heptapeptide inserts 
sequenced; of these, 23 sequences were unique. A 3D molecular model was created for 
the ACKR3/CXCR7 N-terminus by mutating the corresponding region of the crystal 
structure of CXCR4 with bound SDF1/CXCL12. A ClustalW alignment was performed 
on each peptide sequence using the entire SDF1/CXCL12 sequence as the template.  
The 23-peptide sequences showed similarity to three distinct regions of the 
SDF1/CXCL12 molecule. A 3D molecular model was made for each of the phage peptide 
inserts to visually identify potential areas of steric interference of peptides that simulated 
CXCL12 regions not in contact with the receptor’s N-terminus. An ELISA analysis of the 
relative binding affinity between the peptides identified 9 peptides with statistically 
significant results. The candidate pool of 9 peptides was further reduced to 3 peptides 
based on their affinity for the targeted N-terminus region peptide versus no target peptide 
present or a scrambled negative control peptide.  
The results clearly show the Phage Display protocol can be used to target a 
synthesized region of the ACKR3/CXCR7 N-terminus. The 3 peptides chosen, P20, P3, 
  
and P9, showed no effect on the viability or proliferation upon exposure to MCF-7 and 
U87-MG cells. Membrane binding, colocalization, and cellular uptake were confirmed by 
whole-cell ELISA and confocal microscopy. The recovered peptides did not activate the 
receptor as confirmed by a β-arrestin recruitment assay. The data shows that the peptide 
sequences recovered from the phage display protocol are viable candidates for targeting 
cancer cells and delivering material to them.  
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CHAPTER I 
 
INTRODUCTION 
 
 
Current Cancer Treatments and Challenges to Delivery 
 
 Cancer is one word that no one wants to hear. Instantly images of the effects of 
chemotherapy and radiation appear in people’s minds. Individuals losing their hair, 
becoming frail and nauseous from the treatments, the loss of energy, isolation from 
friends and family, trips to the hospital or and many times it ends in death. Standard 
chemotherapy using anthracyclines such as doxorubicin aka “Adriamycin” or 
daunorubicin aka “Daunomycin”, a vinca alkaloid like vincristine aka “Oncovin”, and 
paclitaxel aka “Taxol” has traditionally attacked the body in a systemic fashion and 
eventually some of it makes it to the site of the tumor [
1
]. The protocols typically require 
multiple applications due to their inefficiency and this in turn increases or prolongs the 
suffering of the patient.  
The drugs used may even have limits on the amounts individuals are exposed to 
such as the cardiotoxicity associated with anthracycline therapy [
2,3
]. Researchers were 
able to show that incorporating the drug within a lipid bilayer, a liposome, for delivery 
reduces the systemic toxicity by increasing the amount of drug delivered directly to the 
tumor and reducing the amount available for the rest of the body [
4
]. Vincristine, an 
antineoplastic alkaloid, can be lethal or severely neurotoxic depending upon the injection 
site [
5,6
]. Paclitaxel can also cause death and hypersensitive reactions such as 
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hypotension, bradycardia, and hypertension [
7
]. As these particular examples have shown, 
sometimes the worst part of cancer is the actual treatment and not the disease itself.  
One way to dramatically improve the efficiency of these anticancer treatments is 
to target membrane bound molecules such as glycoproteins and glycolipids or receptors 
expressed on the extracellular surface of cancer cells and deliver the material directly to 
the cells [
8-12
]. The purpose of these ligand-targeted therapeutics (LTTs) and drug 
delivery vehicles are to increase deliverability that would in turn decrease the overall 
amount of chemotherapeutics or other compounds the patient is exposed to and enhance 
the anti-cancer effect on the tumor cells [
1,10,13,14
]. The end result is a faster recovery from 
the reduced side effects and quicker elimination of the targeted tumor cells. The anti-
cancer drugs can be allowed to be passively uptaken by the cancer cells or targeted by 
conjugating them directly to peptides or antibodies (LTTs) [
1,10,13,14
].  
Relying on the passive mechanism requires that the tumor vasculature is present 
versus its absence in the necrotic regions and the size of your treatment is ~100nm-780 
nm in order to make it through the gaps of the leaky endothelial cells [
11
]. This increased 
in size of the fenestrate or opening in the tumor blood vasculature from less than ~10nm 
to roughly 600nm or more is called the enhanced permeability and retention (EPR) effect. 
If the delivery component is a vehicle like the liposome mentioned for the delivery of 
doxorubicin and it is less than 200nm, it will be retained in the tumor environment for an 
extended period of time due to limited or missing drainage by the lymphatic system [
15
]. 
This method can not only deliver drugs, like apomorphine, throughout the body but can 
also deliver imaging agents such as quantum dots (QDs) encapsulated in a 140 nm 
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liposome across the brains primary defensive mechanism for seclusion and isolation, the 
blood brain barrier (BBB), for the treatment of CNS cancers and diseases [
16
].  
The size of the molecules or compounds will have a dramatic effect on how the 
body handles them. Systemic application of liposomes greater than 400nm will typically 
result in opsonization in the blood followed by rapid uptake by macrophages of the 
reticuloendothelial system (RES). The uptaken liposomes then primarily accumulate in 
the liver and spleen; however this accumulation effect may present other problems by 
quickly lowering the levels of phagocytic cells in these organs while undergoing 
chemotherapy [
17
].   
Bypassing the Blood Brain Barrier (BBB) 
 
The EPR effect can be useful when targeting tumors outside the central nervous 
system (CNS). Unfortunately the blood brain barrier does not provide such access and is 
characterized by a lack of fenestrations and the presence of tight junctions between the 
endothelial cells. It also contains a combination of influx and efflux transport proteins 
that monitor the movement of molecules into and out of the brain and blood stream [
18
]. 
The continuity of the system can be compromised or altered in the most aggressive and 
terminal cases of brain cancer, glioblastoma (GBM). It has been shown that the blood 
brain barrier can remain intact, contain pores up to 3 µM, or have tumors with permeable 
cores and structurally intact fringes or edges [
18
].  
Given this strong line of defense, without using a highly invasive surgical 
procedure, other means of crossing or disrupting the blood brain barrier to deliver 
anticancer compounds and imaging agents to the intracranial space are necessary. There 
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are several approaches to accomplish this task. The chemical method uses a hypertonic 
solution of Mannitol or Alkylglycerol to shrink the endothelial cells and create temporary 
openings [
19
]. The physical method uses electromagnetic radiation in the form of 
ultrasonic waves to induce cavitation or the thermal effects of focused ultrasound waves 
to induce temporary permeability [
20,21
]. Lastly, permeation enhancers such as the 
surfactants DMSO and Polysorbate (Tween-80) are used to increase transport across the 
blood brain barrier [
19
]. 
The ability to bypass the blood brain barrier is possible by utilizing intranasal 
delivery. Using a phage display protocol (Ph.D.-C7C), researchers found a disulfide-
constrained heptapeptide that translocated to the brain within 30 minutes.  This peptide 
targeted the brain at a level 50 times higher than non-specific phage peptides and was 
found in high concentrations along the olfactory nerve post nasal application [
22
]. The 
phage display protocol is ideal for this type of desired targeting specificity. Billions of 
candidate amino acid sequences can be tested simultaneously, and then separated down to 
the single phage. This provides the ability to isolate individual peptide sequences for 
further testing of their binding specificity and potential effects on cell proliferation, 
viability, and downstream signaling. Luckily short peptide sequences or small lipophilic 
molecules are not the only things that can be delivered via the nasal cavity.  
Experimentation has also shown that it is possible to deliver whole cells, neural 
stem/progenitor cells (NSPCs), via the olfactory pathways and the microvasculature of 
the nasal mucosa. NSPCs had the ability to intranasally target the main site of 
glioblastoma xenografts within six hours of treatment as well as small satellite tumors 
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located away from the main tumor mass. The NSPCs did not accumulate in the brain 
most likely due the lack of chemotactic signaling molecules, chemokines, generated by 
the tumors and nearby brain parenchyma [
23
]. Given the ability to deliver something as 
large as whole cells, this noninvasive method of treatment deserves further study.  
Chemokines and their Receptors 
 
The 7-13 kDa protein signaling molecules or chemokines necessary for NSPC 
homing to tumor sites are a large family of small cytokines that can be functionally 
identified in three primary ways: pro-inflammatory for mediating the migration of 
leucocytes (CXCL11/interferon-inducible T cell alpha chemoattractant (I-TAC)), have 
critical roles in developmental vasculogenesis and cardiogenesis (CXCL12/stromal-
derived factor (SDF-1)), and maintaining homeostasis via regulation of stem cell pools 
for tissue renewal and tissue repair (CXCL12/SDF-1) [
24,25
]. The chemokines are divided 
into five groups or families (CC, CXC, CX3C, CX, and XC) and named for the location 
of two N-terminal residues of four cysteines and the number of amino acids between 
them or lack of one of the cysteines. For example, in the CC chemokines the cysteines are 
next to each other with no amino acids between them. In the CXC chemokines, there is 
one amino acid between the cysteines and in CX3C there are three amino acids between 
the cysteines.  
The CXC chemokines are also structurally considered ELR-positive or ELR+ due 
to the presence of a three amino acid motif (Glu-Leu-Arg or “ELR”) just ahead of the 
first cysteine residue or ELR-negative (ELR-) if it is missing [
26-30
]. Typically the 
presence or absence of the ELR motif defines the role of the chemokine as pro-
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angiogenic (+) or anti-angiogenic (-). This is not the case for CXCL12/SDF1 which is 
(ELR-) and pro-angiogenic and yet CXCL11/I-TAC is also (ELR-) and it is anti-
angiogenic [
26-30
]. In glioblastomas (GBMs), the transformation of gliomas to malignant 
high-grade GBMs is characterized by a large increase in vasculature and is considered to 
be instrumental for tumor growth. This flipping of the “angiogenic switch” is influenced 
increased levels of pro-angiogenic factors including chemokines and their associated 
receptors [
30-32
]. Given that angiogenesis is considered a “hallmark” of cancer, the ability 
of ACKR3/CXCR7 to bind both of these chemokines and either promote or inhibit 
angiogenesis or vasculogenesis shows just how important it is to the maintenance of the 
tumor environment [
26-35
].  
All of the receptors for chemokines are named for the class of chemokine they 
bind and all are known to be seven-transmembrane G protein coupled receptors due to 
their activation of intracellular signaling pathways via G proteins [
24,25
]. This can be seen 
in the receptors for the previously mentioned CXCL11 and CXCL12. The receptors for 
these two chemokines are CXCR4 and CXCR7. It is important to note that the CXCR7 
receptor is classified as atypical, hence it`s renaming to ACKR3/CXCR7, due to its 
ability to activate signaling pathways via β-arrestin-2 proteins and not G coupled proteins 
[
36
]. The ACKR3/CXCR7 receptor still holds some secrets as there is evidence to show 
that it can activate the Erk1/2 and Akt pathways via Gi/o proteins upon stimulation with 
either CXCL11/12 in primary rodent astrocytes and human glioma cells [
37
].  
Although chemokines and their receptors are only found in vertebrates, there are 
homologues to these genes in some viral genomes implying the sequences have been 
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acquired by these viruses to increase their infectivity [
24,25
]. The seven transmembrane 
domain receptors for chemokines also contain a highly conserved sequence (DRYLAIV) 
in their second extracellular loop which is necessary for the coupling of G proteins and 
downstream activation of signaling pathways [
38-40
]. This is reflected in the altered 
sequence of ACKR3/CXCR7 (DRYLSIT) [
34
]. It would appear the divergent sequence is 
different enough to initiate β-arrestin-2 signaling in some cells and similar enough to 
initiate Gi/o signaling in others [
38-40
]. Based on all of the previous information, it is easy 
to see that the atypical chemokine receptor ACKR3/CXCR7 is an important target for 
anti-cancer therapy. 
The ACKR3/CXCR7 Receptor as a Target 
 
 The ideal candidate for targeting multiple cancer types would therefore be 
present in large numbers on the extracellular surface and have the ability to internalize 
drugs, compounds, or genetic material once they are bound to the surface [
1,41
]. 
ACKR3/CXCR7 is expressed at high levels on multiple cancer cell types and vasculature 
associated cells such as endothelial progenitor cells (EPCs). ACKR3/CXCR7 was shown 
to be necessary for increased EPC proliferation, anti-apoptotic effects, and cell-to-cell 
adhesion [
42,43
]. It has also been associated with angiogenesis in at least five types of 
cancer including prostate, hepatocellular carcinomas, bladder, kidney, and meningioma 
[
33,44-50
]. ACKR3/CXCR7 plays an integral role in the proliferation of roughly nine types 
of cancer that also include breast, lung, pancreatic adenocarcinoma, cervical, colorectal, 
and gliomas [
51-61
]. This receptor has also been implicated in the metastasis or migration 
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of over ten different type of cancer. Some of those not previously mentioned are liver, 
rhabdomyosarcoma, and neuroblastoma [
62-64
].  
ACKR3/CXCR7 has the ability to recycle between the plasma membrane and the 
cytoplasm without the need for ligand binding and activation of the receptor making it a 
highly desirable target [
65,66
]. All of the previously mentioned properties were taken into 
consideration when we were identifying our target of interest the atypical chemokine 
receptor ACKR3/CXCR7. Additionally, the characteristics necessary for blood brain 
barrier passage was into consideration in order to determine the vehicles size and type of 
materials we wanted to use in the design of our delivery vehicle. We chose a 100 nm 
liposome made of a C-70 fullerene derivative and egg-PC for its drug loading capabilities 
and its ability to quench reactive oxygen species (ROS) [
67
]. Low levels of ROS in the 
extracellular environment are involved in carcinogenesis and the ensuing cancer 
progression. The ability to scavenge these particles may prove beneficial to the treatment 
by reducing the level of oxidative stress if inducing high levels of ROS are not part of the 
protocol [
68
]. The search for a targeting moiety specific to ACKR3/CXCR7 begins there. 
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CHAPTER II 
 
IDENTIFYING TARGETING MOIETIES 
 
 
Introduction 
 
The identification of cancer cell biomarkers is a driving force in research today. 
The transformation of normal cells into cancerous ones makes the identification of cancer 
cell specific markers extremely difficult. Many of the cancer associated genes are not 
novel and will simply be overexpressed. The overexpression of a plasma membrane 
bound target such as a cell-surface receptor provides the opportunity to fine tune a 
targeted approach for the delivery of drugs, diagnostics, theranostics, and genetic material 
[
69
]. For the identification of cancer associated genes and biomarkers, a major source is 
The Cancer Genome Atlas (TCGA). The cancers chosen have reduced survival rates and 
a large impact on the health and well-being of the general public 
(www.cancergenome.nih.gov/).  
The first cancer studied by TCGA was glioblastoma (GBM), the most common, 
aggressive, and lethal type of CNS cancer [
70,71
]. The average survival time post 
diagnosis is currently 15 months and there are no successful long-term treatments 
available (http://cancergenome.nih.gov). Treatment is limited due to the intracranial 
location and restrictive nature of the blood brain barrier [
21
]. Resection, chemotherapy, 
and radiation treatments have typically only slowed the progression of the disease by few 
months. Personal experience has seen the survival time to be less than 10 months. Over 
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14,000 people are expected to die in the United States from CNS tumors in 2014, a nearly 
9% increase in just the last four years (www.cancer.gov/). At this rate in the United States 
in 2018, on average at least one person every single day in each of the 50 states will pass 
away from CNS tumors. 
Breast cancer was also selected by TCGA for analysis. In the United States, this 
form of cancer primarily affects females and is diagnosed in males less than two percent 
of the time. In women, breast cancer is the most common form of cancer and only trails 
lung cancer in the number of cancer related deaths (www.cdc.gov/). There were over 
207,000 cases of female breast cancer in 2010 and over 19% or approximately 40,000 
related deaths (http://cancergenome.nih.gov). Years of research and early detection 
through education and mammograms have reduced the ratio of deaths per diagnosis.  
The number of new female cases is expected to climb above 232,000 in 2014, 
with the number of predicted deaths near 17%, or again remaining at 40,000 
(www.cancer.gov/). Although 40,000 deaths is significant, that number would be over 
4,640 higher if the ratio had remained the same as in 2010. If the detection rate in women 
maintains its current pace, there will be over 260,000 newly diagnosed cases in 2018. As 
the numbers indicate, the ability to target and treat breast cancer and GBM cells would be 
extremely beneficial to hundreds of thousands of people in the United States alone.   
A Promising Duo: MRI and FUS 
 
The major drawbacks to current cancer therapy are the effects that chemotherapy 
and radiation have on the patients. The debilitating side-effects include loss of hair, 
appetite, and energy, a constant flu-like feeling, and the destruction of otherwise normal 
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cells due to the systemic application of treatments. Cancer patients would have a better 
chance of a quicker and less strenuous recovery if their bodies did not have to deal with 
the extra burden placed upon them by the administration of current anti-cancer therapies 
and invasive surgeries. An extremely promising noninvasive treatment option initially 
developed at Brigham and Women’s Hospital, magnetic resonance imaging guided 
focused ultrasound surgery (MRgFUS), was first approved by the FDA in 2004 for the 
treatment of uterine fibroids and again in 2012 for alleviating the pain associated with 
bone metastases [
72-74
].  
The incorporation of MRI allows for the 3D identification of the tumor volume 
and real-time monitoring of local temperature increases and the accumulation of necrotic 
regions. The technique utilizes multiple ultrasound transducers and focuses the beam 
paths to a cigar shaped central location of the tumor mass to induce localized rapid 
heating at>70⁰C, to thermally ablate the cells or it can be used to induce cavitation and 
mechanically destroy the cells [
75-77
]. Research has shown the technique to be a viable 
option in multiple cancer types including liver, kidney, prostate, and breast [
78-83
]. These 
types of cancer are typically easier to access and the soft tissues are ideal for MRI. As 
with many things, location matters. The efficiency of the technique is affected by the 
location of the tumor and the surrounding environment.   
Given the importance of location, intracranial cancers such as GBM make them 
some of the most difficult to attempt to treat. The MRgFUS protocol applied to GBM is 
referred to as transcranial MRI-guided focused ultrasound surgery (TcMRgFUS) and was 
used with limited success in 2010 [
84
]. The protocol allows for multiple applications with 
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none of the side effects of standard chemotherapy and radiation. Two of the major 
challenges associated with the treatment include properly identifying the tumor`s 
peripheral boundaries to target the focal point of the beam paths and beam distortion or 
secondary skull heating due to variations in skull`s thickness and density [
85-87
].  
Attempts to handle the beam distortion and secondary heating have been made 
with the addition of multiple transducers and constant software monitoring of 
temperature changes. The highly invasive nature of GBM makes the identification of all 
of the tumor`s finger-like projections nearly impossible and will most likely require 
additional components such as chemotherapeutics or genetic material like siRNA in order 
to be a complete regimen [
88,89
]. The procedure could therefore be enhanced by delivering 
contrast agents to the tumor to more properly define the tumor periphery and thereby 
allow a more aggressive and/or more precise application of the ultrasound treatment.  
The power of TcMRgFUS can also be harnessed to increase access to the 
intracranial space by temporarily making the blood brain barrier more permeable to 
compounds or molecules and it can also be used to activate or release certain thermo-
sensitive components or make cells more susceptible to uptake chemotherapeutics, 
diagnostics or theranostics from the extracellular environment [
20,21
]. These additional 
properties can be used to reduce the systemic effect of chemotherapeutics and increase 
the efficiency of applied therapies. Targeting a plasma membrane component such as a 
receptor would allow for the delivery of these materials and thereby increase the overall 
efficiency of the procedure. Chemokine receptors are known to be associated with the 
enhanced progression, increased severity, elevated morbidity rates of different types of 
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cancers, and are typically overexpressed in these conditions [
26,29,50,90
]. For our purposes, 
the ideal target would then be an overexpressed plasma membrane receptor that upon 
binding a compound or molecule will internalize it and deliver material to the cytoplasm 
without requiring activation of the receptor. 
TCGA and the Identification of ACKR3/CXCR7 
 
Our search began with the datasets at TCGA due to their wealth of sequence data 
for multiple cancers and the pre-selection criteria for the cancers studied. TCGA has 
identified the 668 most overexpressed genes in glioblastoma and two plasma membrane 
associated chemokine receptors are in the top 200, CXCR4 and CXCR7 [
70,73
]. The 
endogenous ligand for this pair of receptors, SDF1/CXCL12, was not on the list of 
overexpressed genes [
70,91-94
]. These receptors have been associated with enhancing 
angiogenesis, tumor growth, intravasation, and metastasis of tumor cells in multiple types 
of cancer [
61,95-101
]. These receptors have also been shown to increase the progression of 
WHIM syndrome and the infectivity of several strains of immunodeficiency viruses 
(HIV-1, HIV-2, and SIV) [
102-105
]. CXCR7 is also associated with the increased 
infectivity and proliferation of cells infected with Epstein-Barr virus (EBV), Human T-
lymphotropic virus type 1 (HTLV-1), Kaposi’s sarcoma–associated herpes virus 
(KSHV), and human papillomavirus (HPV) [
54,106-108
]. The ability to target one or both of 
these receptors has broad implications for diagnostic, theranostic, and drug delivery 
capabilities. 
The discovery of a CXC-chemokine, CXCL12 or stromal cell-derived factor 1 
(SDF1), binding to the LESTR/fusin receptor resulted in the renaming of the receptor to 
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CXCR4 [
109
]. CXCR4 was presumed to be the sole receptor for SDF1 and has been well 
characterized including the elucidation of the receptor`s crystal structure bound to the 
SDF1/CXCL12 ligand [
110
]. The other receptor, CXCR7, was originally identified as 
RDC1 [
111,112
]. Shortly after discovery, the receptor was misidentified as a vasoactive 
intestinal peptide (VIP) receptor [
113,114
] and later reclassified as an orphan G-protein 
coupled receptor [
115
]. It was also known as RDC1/GPRN1 and predicted to exist as two 
tissue specific subtypes which bound an unknown ligand [
116
]. In 2005, the RDC1 
receptor was shown to also bind SDF1 in the presence of CXCR4 and this resulted in the 
renaming of the receptor to CXCR7 [
93
]. Like other chemokine receptors, CXCR7 has 
more than one ligand and it has been shown to bind interferon-inducible T-cell alpha 
chemoattractant (I-TAC/CXCL11), a known ligand of CXCR3 [
51,63
].  
The role of CXCR7 in cellular processes varies from the apparent scavenging of 
SDF1 and I-TAC as it constantly recycles between the plasma membrane and 
intracellular regions, due to atypical β-arrestin signaling instead of the G-protein 
signaling typically associated with GPCRs [
37,61,65,117
]. Additionally, CXCR4 and CXCR7 
have been shown to heterodimerize and work together to mediate the response to the 
presence of SDF1/CXCL12 [
94,95,101,118
]. CXCR7 mRNA is typically expressed at low 
levels and often only intracellularly expressed in several types of normal tissues and cells, 
including several types of leukocytes, differentiated neurons, and vascular endothelial 
cells [
93,119-121
]. CXCR7 protein overexpression results in or increases expression at the 
plasma membrane and has been associated with multiple types of cancer, including 
breast, renal cell carcinoma, pancreatic, neuroblastoma, glioblastoma, papillary thyroid 
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carcinoma, lung, colon, melanoma, Schwann cell and meninges tumors, endometrial, 
prostate, and bladder [
29,44,48,50,52,59,60,98,100,101,122-124
]. The knowledge base of CXCR7 
continues to evolve and the receptor was recently reclassified as the atypical chemokine 
receptor ACKR3 [
125
]. 
A highly specific and productive method for the identification of cell targeting 
moieties is the phage display protocol. This method allows for the rapid identification and 
isolation of peptides that will bind the target of interest. The peptides have the distinct 
advantages of being easily reproducible, inexpensive, and stable for long term storage, 
versus the production time and costs and potential immunogenicity of monoclonal 
antibodies (mAbs) [
1
]. The protocol has been successfully used to target a variety of 
cancers and membrane components including gliomas [
126,127
], prostate cancer [
128,129
], 
cancer stem cell-associated marker CD133/Prominin-1 [
130
], breast cancer [
97,131,132
], 
gastric cancer [
133
], ovarian cancer [
134
], endometrial cancer [
98
], and primary Medullary 
Thyroid Carcinoma [
135
].  
The results of these experiments indicate that the phage display protocol could be 
used to target CXCR4 or CXCR7. Using a synthesized portion of the N-terminus region 
of ACKR3/CXCR7 and modified M-13 phages, we identified and characterized 23 
candidate amino acid sequences with an affinity for this region. Further side by side 
ELISA comparison reduced that number to three. Our findings imply that the identified 
peptide sequences could be used to target the membrane bound form of ACKR3/CXCR7 
and thereby regulate its response or availability to the endogenous ligand SDF1/CXCL12 
and viral particles. 
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Materials and Methods 
 
Comparison and Identification of Sequence Similarities  
The amino acid sequences from ACKR3/CXCR7 
(www.uniprot.org/uniprot/P25106) and CXCR4 (www.uniprot.org/uniprot/P61073) were 
recovered from UniProtKB and loaded into the sequence alignment editor BioEdit 
(www.mbio.ncsu.edu/bioedit/bioedit_backup.html) for alignment.  
Epitope Mapping of ACKR3/CXCR7 and CXCR4 N-terminus Regions  
Epitopes were identified using IEDB Analysis Resource Antibody Epitope 
Prediction tool <http://tools.immuneepitope.org/tools/bcell/iedb_input>. Three methods 
were used: Emini Surface Accessibility Prediction, Kolaskar & Tongaonkar Antigenicity, 
and Bepipred Linear Epitope Prediction. The sequences for the ACKR3/CXCR7 and 
CXCR4 N-terminus regions were analyzed independently of each other. 
Scrambled Negative Control Sequence Generation  
The scrambled negative control sequence was generated using EMBOSS 6.3.1: 
shuffleseq software (<http://mobyle.pasteur.fr/cgi-bin/portal.py?#forms::shuffleseq>). 
The ACKR3/CXCR720 amino acid N-terminus sequence 
(FDYSEPGNFSDISWPCNSSD) was entered and 100 runs were performed. The chosen 
scrambled sequence had the least sequence similarity. A cut-off value of no more than 
three identical amino acids in a row (sequence or group) in either the forward or 
backward direction with the ACKR3/CXCR7and CXCR4 N-terminus template regions 
was used to eliminate candidate sequences. The Scrambled peptide fragment was 
purchased from Bio-Synthesis (www.biosyn.com/).  
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Phage Display (Ph.D. ™-7 Phage Display Peptide Library Kit)  
The target ACKR3/CXCR7 N-terminus region peptide was purchased from Bio-
Synthesis (http://www.biosyn.com/). The Surface Panning Procedure (Direct Target 
Coating) was used following the manufacturers protocols for phage capture (Ph.D. ™-7 
Phage Display Peptide Library Kit - New England BioLabs NEB). Three rounds of 
selection were performed.  Individual phages (blue plaques) were then amplified 
separately at 37°C for 4.5 hours in an overnight ER2738 culture diluted 1:100 in LB. The 
solutions were centrifuged for 14,000 rpm for 30 seconds. The supernatants were 
transferred and respun. The upper 80% of each was retained, diluted 1:1 with sterile 
glycerol, numbered, and stored at -20°C. Prior to storage, the phage stocks were titered to 
confirm they were above the desired 10
20
 plaque forming units (pfu) per 10 µl level. 
DNA Sequencing of Phage and Phage Targeting Peptide Sequence Identification 
Eurofins MWG Operon (www.operon.com/default.aspx) sequenced 3 rounds of 
samples 3 times each, 29 samples total, and the nucleotide sequences were saved as .ab1 
files on their website. The stored .ab1files were loaded into the assembly editor, BioLign 
(www.mbio.ncsu.edu/bioedit/bioedit_backup.html), for chromatogram analysis to 
identify unknown nucleotides in the region of interest. Any unnamed base calls, 
designated “N” in the.ab1files, were identified by systematically comparing multiple 
sequencing runs of the same sample, identifying and declaring the most probable 
nucleotide for that position, and then saving the updated sequence file as a .gb file. The 
.gb files were loaded into the sequence alignment editor BioEdit, reverse transcribed, 
NEB insert bookend sequences identified, and the inserted heptapeptide region of the 
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M13 genome used in targeting was identified. Identical amino acid sequences were 
analyzed for experimental procedure cross-contamination by comparing the original 
nucleotide sequences (.ab1 files) against each other. 
Phage Peptide Insert Sequence Characterization  
Each phage heptapeptide insert sequence was characterized with the EXPASY 
ProtParam tool (http://web.expasy.org/protparam/) for theoretical isoelectric point (pI), 
estimated half-life, instability index, aliphatic index, and grand average of hydropathicity 
(GRAVY). A ClustalW sequence alignment (BioEdit) was performed individually for 
each recovered peptide sequence against the endogenous ligand SDF1. Regions of the 
SDF1 ligand that showed similarity to the phage insert sequences were located and these 
residue positions identified and entered into an Excel spreadsheet. The identified SDF1 
residues were then highlighted by themselves in Maestro alongside the mutated 
ACKR3/CXCR7 N-terminus 3D model in order to confirm that candidate SDF1 residues 
were in a position to bind the N-terminus target. 
Phage ELISA Assay  
To coat a 96-well microplate for ELISA, four wells were used to test each phage: 
2 wells with ACKR3/CXCR7N-terminus (1 experimental well with phage and 1 blank 
no-phage negative control, 1 Scrambled peptide negative control well, and 1 BSA 
blocked/No-target negative control well. Individual wells were incubated overnight 
with50 μls of one of the following solutions: (2 wells) 10 μg/ml solution of the 
ACKR3/CXCR7N-terminus target, (1 well) a 10 μg/ml solution of the Scramble peptide, 
and (1 well) a BSA 5mg/ml solution, all solutions in 0.1 M NaHCO3 pH 8.6, at 4°C with 
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gentle agitation. The coating solutions were removed; the plate was blocked with BSA, 
and then washed with TBST. The 23 phage samples were randomly divided into 3 groups 
for plating and these groups of phages were tested together on the same day using 
separate wells in a 96-well microplate.  
Except for the Blank No-phage negative control, individual wells were incubated 
with 100 μl of a single phage stock at room temperature for 2 hours with gentle agitation. 
The phage solution was removed and the wells were washed with PBS(1X). A 100 μl 
solution of anti-M13 antibody (anti-M13-HRP conjugate, GE Healthcare #27-9421-01) 
diluted 1:1000 in PBS(1X)  was added to each well and allowed to incubate for 2 hours at 
room temperature. The antibody was removed and the plate was washed with PBS(1X). 
100 μls of the TMB ELISA Substrate Slowest Kinetic Rate (Abcam - ab171527) was 
added and allowed to develop for 40 minutes. The reaction was stopped by adding 100 
μls of the 450 nm Stop Solution for TMB Substrate (Abcam - ab171529). Each phage 
was tested a total of three times over three different days. The plates were read on a 
BioTek microplate reader at 450 nm and the values were exported into an Excel 
spreadsheet.  
Statistical Analysis of ELISA Data  
The raw data was initially arraigned into 9 tables (3 sets x 3 trials) with 7 or 8 
phage samples per table. The data was standardized using the average Blank No-Phage 
Negative Control values from trial 1 as the standard level of background noise. The 
standard No-Phage Negative Control value was divided by each of the remaining 8 Blank 
No-Phage Negative Control values on a plate by plate basis in order to determine the 
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conversion factor for each plate. The conversion factor for each plate was applied to all 
values within that plate. The new values were normalized by subtracting the standard 
background noise baseline value from all of the remaining values on that plate.  
Individual normalized values for each phage were then grouped into 3 tables for 
statistical analysis (t-Test: Paired Two Sample for Means). The values from the 3 trials 
were then grouped as follows: (1) Experimental values vs No CXCR7 Negative Control 
values and (2) Scrambled peptide values vs No CXCR7 Negative Control values. The 
Level of Significance used was 5% (Alpha α = 0.05). The threshold cutoff values used 
were: * t-test Critical one-tail = 2.92 and ** t-test Critical two-tail= 4.30. Vertical error 
bars in both directions were set based on the Standard Error Margin (SEM). 
3D Homology Modeling of the CXCR7 N-terminus and Recovered Phage Peptide 
Structures 
Maestro Version 9.2.112 - MMshare Version 2.0.111 - Windows-x64 software 
was used for 3D homology modeling and Phage Peptide construction. The 38 residue N-
terminus of the CXCR4 crystal structure with endogenous ligand SDF1/CXCL12 bound 
to it (PDB ID: 2K04) served as the template model [
110
]. The N-terminus residues 1-38 of 
CXCR4 were trimmed to residues 6-25 (IYTSDNYTEEMGSGDYDSMK). This 
sequence was saved as a Maestro project or “.prj” file. This .prj file was reloaded and 
then mutated to the corresponding N-terminus residues (6-25) of ACKR3/CXCR7 
(FDYSEPGNFSDISWPCNSSD) and saved as a separate .prj file. The transformation of 
the CXCR4 sequence into ACKR3/CXCR7 was accomplished by selecting individual 
residues of the CXCR4 sequence and then mutating them into the 
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ACKR3/CXCR7sequence using the “Mutate Residue” command. Due to identical 
sequence similarity at positions S9 (Ser9), S18, and S23 between CXCR4 and 
ACKR3/CXCR7, these Serine residues were used as anchor locations for the necessary 
sequence mutations into ACKR3/CXCR7.  
The two individual .prj files (CXCR4 N-terminus and ACKR3/CXCR7 N-
terminus) were imported into the same workspace and overlaid upon each other. Stacking 
the two individual chains of CXCR4 and ACKR3/CXCR7, using only Chain D for each 
(Ball and Stick or Tube Mode) in this manner made it possible to include the bound 
SDF1/CXCL12 residues 3-67 (Chain C in CPK mode) in their original positions. This 
method of stacking made it possible to identify potential steric conflicts due to mutation 
of the previously existing CXCR4 residues. Potential steric conflicts were resolved using 
commands such as “Adjust - Quick Torsion” or “Adjust - Angle” on each mutated 
residue. The 7-amino acid sequence of each of the identified 23 Phage Peptide sequences 
was transformed into a 3D model and saved as individual PDB (.pdb) files. The models 
were constructed using commands such as “Build - Fragments - Amino Acids.” 
Results 
 
Selection and Generation of ACKR3/CXCR7 Test Peptide and Epitope Mapping  
There is no crystal structure of ACKR3/CXCR7 in the RCSB PDB database 
(www.rcsb.org/pdb/home/home.do); however there is a structure of the related receptor 
CXCR4.  To generate a test target peptide that takes into consideration structural and 
domain elements that may be important for the selection of putative targeting peptides 
that work in vivo, we used the extra cellular N-terminal peptide sequence of CXCR4 as a 
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backbone model.  The ACKR3/CXCR7N-terminus was numbered M1-K40 and the 
CXCR4 N-terminus was numbered M1-K38. As seen in Figure (1), both 20 amino acid 
N-terminus regions have a Serine (S) residue at positions 9, 18, and 23. The Ser18 
residue in ACKR3/CXCR7and CXCR4 is the site of O-linked Glycosylation. In addition, 
CXCR4 has post-translationally modified residues (N-linked Glycosylation or 
Sulfonation) at Y7, N11, Y12, and Y21 and two β-sheet folds. One is at S9-N11 starting 
with a serine residue and ends with an asparagine residue. The other is at Y21-S23 
starting with a tyrosine and ending with a serine (www.uniprot.org/uniprot/P61073). 
ACKR3/CXCR7 has predicted or verified corresponding similarly modified residues at 
Y8, N13, and N22 and a β-sheet fold at S9-N13 that also starts with a serine residue and 
ends with an asparagine residue (www.uniprot.org/uniprot/P25106). 
To identify and characterize potentially important epitopes within the N-terminus 
of ACKR3/CXCR7, we performed comparisons on both CXCR4 and ACKR3/CXCR7 as 
shown in Figure (1).  Analysis of the N-terminal CXCR4 region revealed four epitopes. 
Three of these (Kolaskar & Tongaonkar I4-D10 and M24-E31, Bepipred Linear Epitope 
S9-E31) spanned portions of the 20 amino acid region isolated and one (Bepipred Linear 
Epitope N33-A34) was outside this region. A complimentary analysis of the homologous 
region of ACKR3/CXCR7 examined contained three complete epitopes identified by 
sequence analysis and includes part of a fourth area as shown in Figure (1). The complete 
epitopes included the area identified by Emini Surface mapping F6-N13, the two regions 
identified by Bepipred Linear Epitope mapping S9-I17, and W19-N22. The fourth area 
identified by Kolaskar & Tongaonkar mapping spanned I17-P35 and extended 10 AA`s 
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beyond the targeted region. However, the first 9 AA`s (17-25) were included in the target 
region.  From this analysis we selected a 20 amino acid sequence from 
ACKR3/CXCR7that we used for the phage display screen. 
Selection and Generation of Scrambled Negative Control Sequence  
Based on a comparison of the EMBOSS 6.3.1: shuffleseq software generated 
sequences and the corresponding (ACKR3/CXCR7)/CXCR4 regions; the sequence 
(SWESFPNDCSYGDNDFSPIS) was the only scrambled variation to meet the necessary 
criteria as seen in Figure (2). Scrambled regions that were identical or similar to 
ACKR3/CXCR7or CXCR4 were identified and highlighted. Three of the eliminated 
candidate sequences, Example 1, 2, and 3, and the legend for amino acid grouping and 
classification have been included for comparison in Figure (2).  
Phage Targeting Peptide Sequence Characterization 
Using this 20 amino acid region, we performed a phage display screen using a 7 
amino acid M13 phage library (NEB). The initial phage display experiments produced 
over 100 candidate plaques and 30 of those were selected for analysis. Prior to sequence 
analysis; the 30 phages had been labeled P-01 to P-24 and C1-C6. The amino acid 
sequences for 29 of the 30 phage inserts were successfully identified as seen in Figure 
(3).No usable sequence data was recovered from phage P-12. Of these 29 amino acid 
sequences, 23 were unique. No evidence for cross-contamination for the identical 
sequences was found after a comparison of their nucleotide sequences as shown in a 
comparison of the coding sequences in Figure (3).The results of the EXPASY ProtParam 
analysis (Isoelectric point (pI), estimated half-life, Instability Index, Aliphatic Index, and 
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GRAVY) yielded a wide variety of values across the categories and are listed in Figure 
(3).  
The pH at which these peptides would have a neutral charge, the isoelectric point 
or pI, showed values that ranged from 5.24 (P-08, P-C4, and P-06) up to 12.00 (P-18 and 
P-17). Of the 29 identified putative ACKR3/CXCR7 targeting peptides, 15 had pI values 
of less than 6.00 and 6 had a value of 9.77 (±0.02). The influence of the positively 
charged arginine (R) and lysine (K) residues versus the negatively charged aspartic acid 
(D) and glutamic acid (E) residues is reflected in the pI values. There were multiple 
peptides with an (R) or (K) residue and they had pI`s above 8.44, all but one was ≥9.75. 
The presence of 2 (R) residues increased the pI to 12.00. Peptides P-08 and C4, with a 
single (E) residue, had lower pI values of 5.24. Peptides P-02 and P-09 contained a (D) 
and an (R) residue and their values were slightly higher at 5.50 and 6.74 respectively. 
To determine the potential lifespan in-vivo or the usable working time limit of the 
recovered peptide sequences, it was necessary to calculate the amount of time required to 
degrade the peptide. The estimated in-vivo half-life for each peptide sequence was 
calculated using the N-end rule [
136-138
]. The values were calculated using mammalian 
(rabbit reticulocytes) cells as the host organism. Peptides P-3 and P-5 showed the fastest 
overall degradation rates with a value of 0.8 hrs. Peptides P-07 with valine (V) or P-16 
and C1with glycine (G) at the N-terminus had the slowest rate of degradation rates of 100 
hrs and 30 hrs. Peptides with an arginine (R) or glutamine (Q) at the N-terminus had the 
fastest degradation rates, ≤1hr. Therefore, peptide P-7 could remain viable in the system 
for 100 times longer than peptides P-3 and P-5. Another representation of a peptides 
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intracellular stability is the Instability Index. This value takes into consideration the 
combinations of dipeptides within a sequence and not just the amino acid represented at 
the N-terminus. The Instability Index (II) was predicted for each peptide and values less 
than 40 were considered to indicate a stable protein [
139
]. The five peptide sequences 
predicted to be the most stable were P-08 (-7.67), C-2 (-10.36), P-07 (-12.90), C-1 (-
17.01), and P-04 (8.80). Peptide P-18 was predicted to be the least stable with the highest 
II at 133.30 and would therefore break down the quickest. A peptide sequence such as C-
1 would be expected to survive in the system for the longest period of time and be 
available in a larger time window for targeting the cells of interest. 
The Aliphatic Index is indicative of the alanine (A), valine (V), isoleucine (I), and 
leucine (L) content of the recovered peptides and increasing values are considered to 
reflect increasing thermostability [
140,141
]. The hydrophobic natures of these residues are 
different from those of aromatic amino acids and are a primary contributing factor to the 
increase in thermostability. The calculated values range from 0.00 for peptides P-06, P-
09, and C-2 that contained none of those residues up to 208.57 for peptide P-08 that 
contained one each of the (I) and (L) residues and two (L) residues. The majority of the 
values were ≥ 55.71 with only eight of the values ≤ 28.57. Peptide C-1 had a value of 
14.29 and would be less stable than P-08 at elevated temperatures. The results here are 
indicative of the thermal relationship associated with the Aliphatic Index. The Aliphatic 
Index for P-08 is over 14.6 times higher than the value for C-1. The Instability Index (II) 
for C-1 was only 2.2 times higher than the value for P-08. The stability of these two 
peptides varies greatly when temperature is a concern.  
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Whether or not a particular peptide sequence is hydrophilic or hydrophobic will 
affect how it is modified or utilized later and may impact the number of ways it can be 
incorporated into a protocol. Hydrophobic components such as cholesterol are known to 
self-assemble and insert themselves in lipid bilayers such as those associated with cellular 
membranes and liposomes. Extremely hydrophobic peptide sequences functionalized to 
cholesterol could potentially interfere with their ability to self-assemble properly and 
orient the conjugated molecule with the peptide sequence exposed to the exterior 
environment and the cholesterol component imbedded within the bilayer. The hydrophilic 
or hydrophobic nature of the peptides was determined by calculating the grand average of 
hydropathicity (GRAVY). This same technique has been used to predict the location of 
membrane spanning portions of proteins and receptors based on the hydrophobic nature 
of the residues examined. The level of hydropathicity was based on using isoleucine (I) 
as the most hydrophobic at +4.50 and arginine(R) as the most hydrophilic at -4.50 
[
142
].The scores varied from +1.143 for peptide P-08 to -2.543 for peptide P-09. The 
majority of the sequences were of a hydrophilic nature as there were only six peptides 
with positive values. 
Comparison with SDF1 
To determine whether the identified peptides mimicked the ligand of the 
ACKR3/CXCR7 receptor, SDF1, we performed a ClustalW analysis comparing the 
identified peptides to the protein sequence of SDF1 as seen in Figure (4).  The entire 93 
amino acid sequence of SDF1 (www.uniprot.org/uniprot/P48061) was used for the 
analysis to include all potential binding regions of the molecule [
51,93,118,143,144
].  A 
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ClustalW analysis indicates the recovered putative ACKR3/CXCR7 targeting peptides 
fell into three clusters. None of the peptides were predicted to mimic the first 20 residues 
of the endogenous ACKR3/CXCR7 ligand as seen in Figure (4). The three clusters 
consist of SDF1 residues 26-35, 51-55, and 71-85 and showed similarity with ≥25% of all 
peptide sequences tested.  
The number of similar sequences was highlighted in yellow. Due to the presence 
of identical sequences, the sequence for peptide P-13 was used to represent P-13 and P-
19. Also, the sequence for peptide P-24 was used to represent peptides P-24, P-14, P-15, 
P-21, P-22, and P-23. There were 23 sequences total subjected to analysis. Using the 
sequence data for SDF1, the sequence positions of the SDF1 activation motif, Heparin 
and receptor binding sites, and structural elements (turn, β-strand, α=Helix) were 
identified and noted above the SDF1 sequence in Figure (4). Peptides P-16 and P-20 were 
the only two sequences predicted to simulate the activation motif and only nine 
sequences were predicted to simulate regions outside those known to bind Heparin or a 
receptor. 
Phage ELISA Assay 
To determine the specificity and relative affinity of binding of our 23 putative 
ACKR3/CXCR7 targeting peptides to the original peptide target performed an ELSA 
assay using phage against the original target peptide. The values for each ELISA were 
normalized to a control plate with no target and to control with scrambled peptide Figure 
(5).  The goal was to identify peptides which have specific binding to the target peptide 
and showed no non-specific-binding to either the BSA treatment polypropylene surface 
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or 20 amino acid peptide coated surfaces. When compared to a peptide binding a surface 
without a ACKR3/CXCR7 target, we found a broad range of relative binding efficiencies 
with Peptide P-20 having the highest value at 10.3 (ten times greater  than no target 
alone) and P-08 had the lowest at 1 (no better than no target).  A statistical analysis of the 
data reveal that only nine peptides had a value greater than 2.92 which was determined to 
be the significant difference from control (Figure 5). Paired Two Comparison of the 
binding of the putative ACKR3/CXCR7 targeting peptides to the scrambled peptide 
revealed that only eight peptides showed significant binding to the scrambled peptide 
(Figure 5).  From these results, five identified peptides showed specific high binding to 
the target peptide versus the scrambled peptide: P20, P3, P9, P11, and P4. 
3D Homology Modeling of the ACKR3/CXCR7 N-terminus and Recovered Phage 
Peptide Structures 
The transformation of the CXCR4 N-terminus into the ACKR3/CXCR7N-
terminus had very few instances of steric interference. The ACKR3/CXCR7 homology 
model generated with Maestro as seen in Figure (6) overlays very well with the known 
crystal structure of CXCR4 bound to the endogenous SDF1α/CXCL12 ligand. 
Highlighting the ACKR3/CXCR7N-terminus (F6-D25) in Multicolored BALL & STICK 
mode and overlaying it on top of the corresponding CXCR4 N-terminus (I6-K25) in RED 
thin-tube mode showed an extremely tight fit. The location of the matching serines 9, 18, 
and 23 was identified and then outlined in YELLOW Boxes. The predicted matching 
phage peptide versus SDF1/CXCL12 sequence similarity regions were identified as seen 
in Figures (7, 8, and 9). 
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Discussion 
 
Targeted delivery of contrast agents, or anti-viral and anti-cancer compounds to 
cancerous or infected cells would increase the efficiency of current imaging techniques 
and treatment regimens and decrease all or many detrimental side effects. The associated 
fatigue, loss of appetite, treatment acquired infections, flu-like symptoms, and hair loss 
are typically the result of systemic application of chemotherapeutics, repeated radiation 
exposure, or prolonged use of antibiotics[
1
]. Overexpressed plasma membrane bound 
components that are accessible via the extracellular space are highly attractive targets for 
cell specific delivery. One of these components is the atypical chemokine receptor 
ACKR3/CXCR7. These receptors consist of intracellular and extracellular loop regions 
as well as an extracellular N-terminus tail and intracellular C-terminus tail region. The 
extracellular regions are the most promising areas for targeting.  
The N-terminus tail region of the ACKR3/CXCR7 receptor consists of 40 amino 
acids (#1-40) with position #1 out in the extracellular space and position #40 next to the 
cellular membrane. We chose amino acids #6-25 as our target region. The first five amino 
acids (#1-5) are known to be involved in receptor dimerization (homo/hetero) and could 
be occupied in a dimerized state in-vivo and therefore inaccessible for targeting. Amino 
acid #26 is a cysteine and would have added a potential cysteine-loop formation to our 
target during synthesis. Amino acids #27-29 are hydrophobic and would have changed 
the hydrophilic characteristic of our selected sequence. Epitope mapping of the N-
terminus region of ACKR3/CXCR7 identified four areas of interest and three of these 
would be completely in the region targeted. A portion of the fourth region would also be 
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located here. The importance of the selected 20 amino acid region is highlighted by the 
number of predicted sites in such a short span of amino acids and the presence of a 
structural element such as the β-sheet fold at S9-N13 (Figure 1). The NEB M-13 Phage 
Display protocol provides a cost effective mechanism to quickly and efficiently identify, 
isolate, and amplify protein sequences with target specific binding affinity for such a 
region of interest as this.  
Our experimental data show that the peptides identified via phage display as P-20, 
P-9, and P-3 bound a synthesized portion (F6-D25) of the N-terminus region of 
ACKR3/CXCR7 with a statistically relevant degree of significance using ELISA data. 
They were physically and chemically different from each other based on multiple 
computed characteristics, and were predicted to mimic three different regions of the 
endogenous ligand SDF1/CXCL12 based on a ClustalW comparison against its entire 
sequence. We were also able to generate a 3D molecular model of the synthesized portion 
of the ACKR3/CXCR7 N-terminus region using the known crystal structure of the same 
region in CXCR4 with SDF1/CXCL12 bound to it [
110
]. Our modeling data show no 
areas of potential steric interference when this region is transformed from CXCR4 to 
ACKR3/CXCR7 and the spacing between the Serine residues found in both sequences at 
positions 9, 18, and 23 and the corresponding residues in the bound ligand 
SDF1/CXCL12 is identical.  
Based on our data for these three peptides, peptide P-20 should have the highest 
affinity for the N-terminus region of membrane bound ACKR3/CXCR7and it also has the 
highest predicted potential to activate the receptor and trigger downstream signaling. In 
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total, our data supports the conclusion that peptides P-20, P-9, and P-3 are viable 
candidates for the Phase 2 cell line studies. It is important to note that the degradation 
times are based on the L-peptide form and stability could potentially be improved by 
synthesizing the more stable D-peptide form of the peptide sequence. The peptides were 
presented to the target without the benefit of prior folding by molecular chaperones or 
structural cofactors. 
As previously mentioned, the MRgFUS technique shows great promise in the 
noninvasive treatment of cancer, but is currently limited by incomplete imaging of tumor 
periphery and the ability to deliver sufficient power to the targeted region to completely 
ablate the tumor [
89,145
]. Targeted peptide sequences such as we have discovered are ideal 
components of cell specific delivery systems. The peptide sequences can be 
functionalized with a glycine linker tail (G4) and attached to cholesterol for incorporation 
into liposomes [
146,147
]. We have synthesized potential candidate liposome structures from 
a functionalized C-70 fullerene derivative (ALM, a kind gift from LUNA and Dr. C. 
Kepley) and egg-PC [
148
]. These liposomes were optimized at 99 nanometers (+/- 16 
nanometers) as seen in Figure (10). This type of delivery vehicle with a lipid bi-layer 
allows for the use of hydrophilic core compounds, hydrophobic intramembranous 
compounds, and functionalized membrane embedded compounds [
10,20,149
]. The synthesis 
of liposomes at less than 200 nm makes them ideal candidates for delivery across the 
blood brain barrier via intranasal delivery [
23,150
]. Comparative 3D molecular models of 
the liposomal components, ALM and egg-PC, plus the three phage peptides, P-20, P-9, 
and P-3 can be seen in Appendix A. 
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Modifying the liposomal components also incorporates the ability to control the 
release of included compounds through a temperature sensitive mechanism [
151
]. The 
identification of multiple peptide sequences allows for a multivalent approach to 
functionalization and targeting [
152
]. Additionally, a multivalent approach provides a 
means to continue to target the cell membrane bound receptor even if there are some 
slight mutations or modifications in the N-terminus amino acid sequence. The inclusion 
of contrast agents such as super-paramagnetic iron oxide nanoparticles (SPIONs) in a 
targeted liposome could greatly enhance the ability to visualize a tumor, influence the 
rate of flow of compounds through the use of a localized magnetic field, and also allow 
the use of magnetic hyperthermia therapy to ablate the tumor cells [
153,154
]. These same 
SPIONs could also be used to magnetically separate targeted cells, such as virus-infected 
cells, from the blood stream through a modified dialysis procedure. The addition of a 
gold coating to the SPIONs would further add the ability to use near infrared light to 
thermally ablate these same cells [
155
]. 
In summary, we have identified three heptameric peptide sequences that bind a 
synthesized portion of the N-terminus region of ACKR3/CXCR7, have different physical 
and chemical properties, and are predicted to mimic three different regions of the 
endogenous ligand SDF1/CXCL12. These peptide sequences have the potential to 
provide a new mechanism for targeting of multiple forms of cancer and chronically 
infected cells and thereby increase the efficacy of current treatment regimens, while 
greatly reducing the pain and suffering caused by standard procedures. 
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CHAPTER III 
 
CELL LINE STUDIES WITH SELECTED TARGETING MOIETIES 
 
 
Introduction to Cell Lines 
 
For this study, MCF-7 breast cancer cells were used as the positive control cell 
line. The MCF-7 cell line has been used previously as the cell line of choice for 
experiments involving CXCR4 and ACKR3/CXCR7 [
156
]. Historically, the use of MCF-7 
cells has been associated with the identification and characterization of the 
ACKR3/CXCR7 receptor. In September of 2004 US Patent #US 2004/0170634 A1 
identified an unknown receptor expressed on the surface of MCF-7 cells. That receptor, 
CCX-CKR2, had the ability to bind the endogenous ligands CXL12/SDF-1 and 
CXCL11/I-TAC with high affinity [
157
]. In 2006, again using MCF-7 cells, the CCX-
CXKR2 receptor would be shown to be the same as the previously identified RDC1 
receptor [
112,158
]. The researchers in 2006 would then reclassify the two receptors, CCX-
CKR2 and RDC1, as CXCR7 [
51
]. They would also state that targeting the 
ACKR3/CXCR7 receptor with antagonistic compounds would be beneficial in the 
treatment of roughly 48 types of cancer including breast cancer and glioblastoma [
157
].  
The renaming of the RDC1 receptor to CXCR7 was already supported by another 
group in 2005 due to their competitive binding analysis in T-lymphocytes of the binding 
affinity of ACKR3/CXCR7 for the endogenous ligand SDF1 versus their newly 
discovered antibody, anti-RDC1 mAb 9C4 [
93
]. It is important to note that the region of 
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the ACKR3/CXCR7 N-terminus used to generate their anti-RDC1 mAb 9C4 was four 
amino acids, NSSD, shorter than the region used by our research group. We deemed 
these four missing residues as important due to their specific sequence location or their 
potential involvement in ligand binding and included them for our experimentation. The 
first two missing amino acids include an asparagine, Asn23 or N23, potentially involved 
in post-translational N-linked Glycosylation and a serine, Ser24 or S24, which served as 
the third serine anchor for our sequence analysis and molecular models. The Asn23 
residue in ACKR3/CXCR7 has a corresponding tyrosine residue, Tyr22 or Y22, in 
CXCR4 and this residue has been implicated in cancer metastasis and considered a good 
target for cancer treatment [
159
].  
The Tyr21 residue in CXCR4 not only enhances SDF1 binding but a 
corresponding Tyr21 residue is located in the N-terminus of all of the CXC receptors. 
Only CXCR6 is missing this particular Tyr21 residue [
110,160,161
]. Additionally, the four 
missing amino acids were identified as being components in two of the four epitopes 
discovered during our epitope mapping experiments of the selected ACKR3/CXCR7 N-
terminus region [
67
]. The prior use of the T-lymphocytes to quantify SDF1 binding 
reemphasizes the importance of targeting the ACKR3/CXCR7 receptor and its potential 
use in treatment of HIV and other infectious diseases [
102
]. The ability to inhibit SDF1 
binding has been shown to decrease the infectivity of some HIV strains [
103,104,109,162
]. 
Given the ability of CXCR4 and ACKR3/CXCR7 to bind SDF1 in roughly the same 
region on their N-terminus, the ideal positive control cell line would not express CXCR4. 
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Again the MCF-7 cell line is an excellent choice as our positive control cell line due the 
lack of expression of CXCR4 [
51
]. 
To further test the binding specificity of the three phage display derived peptides, 
P-20, P-9, and P-3; THP-1 monocytes were used as the negative control cell line. THP-1 
cells and primary human monocytes have recently been shown to express high levels of 
CXCR4 but not ACKR3/CXCR7 [
163
]. Therefore, any binding of the phage display 
peptides to the THP-1 cells would potentially indicate a tendency for the peptides to bind 
CXCR4 as well as ACKR3/CXCR7 and thereby limit the specificity required to be used 
as a targeting moiety. 
The choice of a glioblastoma (GBM) based experimental cell line is based on 
personal experience with the debilitating effects and aggressive nature of the disease. The 
suddenness of its appearance, the constant threat of imminent death that surrounds it, and 
the lack of viable treatments make the disease a high priority for our research. Based on 
the prior experience members of our facility have culturing glioma cells; U87-MG 
glioblastoma cells were used as the experimental cell line. One of the defining 
characteristics of glioblastoma is its propensity for invasiveness. Research has shown that 
the hypoxic conditions of gliomas upregulates the expression of ACKR3/CXCR7 and 
U87-MG cells migrate towards SDF1 under these conditions [
57
].  
The U87-MG cell line was also use in a comparative study with infiltrative 
astrocytomas. The data from those experiments showed that the expression of the 
ACKR3/CXCR7 protein rose with malignancy and the receptor was primarily localized 
to the cellular membrane where it is accessible as a target [
164
]. The heterodimeric role of 
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the ACKR3/CXCR7 and CXCR4 membrane bound complex as it pertains to enhancing 
cell migration was investigated. The complex was shown to recruit β-arrestin and activate 
multiple signaling pathways that included ERK1/2, p38 MAPK, and SAPK [
165
]. The 
ability to limit or reduce cell proliferation and the invasiveness of U87-MG cells was also 
shown using a siRNA reduction technique against ACKR3/CXCR7 [
58
].  
The detection of ACR3/CXCR7 on the plasma membrane has had some 
confounding results. Some research has shown large pools of intracellular 
ACKR3/CXCR7 with limited or nominal expression on the U87-MG cell surface [
56,121
]. 
The findings of limited membrane localization may be associated with the ability of 
ACKR3/CXCR7 to constitutively recycle between the cytoplasm and the cell membrane 
[
65,66
]. This can be compared with the large portion of CXCR4 receptors, roughly 70%, 
that are degraded by lysosomes upon internalization. The loss of such a vast number of 
CXCR4 receptors could lead to loss of signaling activity or saturation of CXCR4 and an 
increased role in ligand scavenging by ACKR3/CXCR7 [
166
].  
Thus the utilization of MCF-7 cells that are ACKR3/CXCR7 (+) and CXR4 (-) 
versus THP-1 cells that are ACKR3/CXCR7 (-) and CXR4 (+) will provide a mechanism 
to identify whether or not our phage display peptides have an affinity for 
ACKR3/CXCR7 expressed on the surface of U87-MG cells. The following experiments 
will focus on characterizing the effects of targeting U87-MG cells with our phage display 
derived peptides and determining how the peptides affect cell proliferation, cell viability, 
membrane binding, cellular uptake, and receptor activation. 
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Materials and Methods 
 
The Effect of Phage Peptide Incubation on the Viability of a Small Population of 
MCF-7 Cells 
The populations consisted of 3 wells each containing 5,000 MCF-7 cells, 15,000 
cells total. Cells were grown for 48 hrs in filter sterilized HyClone RPMI (GE 
Healthcare) Complete media (87% RPMI 1640 + 10% FBS (Fisher Scientific) + 1% 
Pen/Strep/Ampho-B 100X (Sigma) + 1% essential amino acids 100X (Sigma) + 1% L-
glutamate 200 mM (Sigma) at 37⁰C in 5% CO2 and then incubated in a 90% media + 
10% (phage stock 10
18
/PBS (1X)) solution (for each phage peptide) for another 48 hrs. 
Control wells included the Standard which only contained media and the PBS (1X) well 
that had 90% media + 10% PBS (1X). Cells were trypsinized and harvested. Live/Dead 
staining was performed with a hemocytometer and Trypan Blue. The average of 10 
counts was used for statistical analysis, t-test with α = 0.05. All analysis were based on 
comparison with the Standard (t Critical one-tail = 1.833 and t Critical two-tail = 2.262). 
The Effect of Phage Peptide Incubation on the Viability of a Large Population of 
MCF-7 Cells 
The population consisted of 1 well each containing 100,000 cells. Cells were 
grown for 48 hrs in RPMI Complete media at 37⁰C in 5% CO2 and then incubated in a 
90% media + 10% phage PBS (1X) solution (for each phage peptide) for another 48 hrs. 
Control wells included the Standard which only contained media and the PBS (1X) well 
that had 90% media + 10% PBS (1X). Cells were trypsinized and harvested. Live/Dead 
staining was performed with a hemocytometer and Trypan Blue. The average of 10 
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counts was used for statistical analysis, t-test with α = 0.05. All analysis were based on 
comparison with the Standard (t Critical one-tail = 1.833 and t Critical two-tail = 2.262). 
The Effect of Phage Peptide Incubation on the Cell Proliferation of MCF-7 Cells 
The populations consisted of 6 wells each containing 25,000 cells. Cells were 
grown for 48 hrs in 100 µl of RPMI Complete media at 37⁰C in 5% CO2 and then 
incubated in a 90% media + 10% phage/PBS (1X) solution (for each phage peptide) for 
another 48 hrs. The negative control population received no phage exposure. A Vybrant® 
MTT assay (Fisher Scientific) was performed according to the manufacturers Quick 
Protocol Option. Briefly, 10 µL of the 12 mM MTT stock solution was added to each 
well and incubated at 37°C for 4 hours. Then 85 µl of media was removed, 50 µL of 
DMSO was added to each well and mixed thoroughly, cells were incubated at 37°C for 
10 minutes, mixed again, absorbance was read on a BioTek microplate reader at 540 nm 
instead of 570 nm and the values were exported into an Excel spreadsheet. All analysis 
were based on comparison with the Standard (t Critical one-tail = 2.920 and t Critical 
two-tail = 4.302) (α = 0.05). 
Whole-Cell ELISA Confirmation of MCF-7 Cell Membrane Binding by Phage 
Peptides Using an HRP Conjugated Anti-M13 Antibody with a TMB Substrate and 
STOP-450 solution 
The populations consisted of 6 wells each containing 25,000 cells. Cells were 
grown for 48 hrs at 37⁰C in RPMI Complete at 5% CO2 and washed thrice with PBS (1X) 
between each step. Cells were blocked for 2 hrs with 1% BSA, washed, and incubated in 
a 90% media + 10% (phage/0.5% BSA) solution (for each phage peptide) for 4 hrs at 
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room temperature or RT (a no-phage negative control was included with 0.5% BSA). 
Wells were washed, incubated with anti-M13 HRP conjugated mAb (GE Healthcare) 
1:2500 for 1 hr, washed, incubated with the TMB substrate (Abcam) for 1 hr, and 
allowed to develop color for 45 minutes. The acidic 450 nm STOP Solution (Abcam) was 
added to stop the enzymatic reaction. Absorbance was read at 450 nm on a BioTek 
microplate reader and the values were exported into an Excel spreadsheet. All phage 
peptide results were compared to the no-phage negative control (α = 0.05) (t Critical one-
tail = 2.920 and t Critical two-tail = 4.302).  
MCF-7 Cells - Membrane Receptor Binding and Cellular Uptake of Phage Display 
Derived Peptides 
Cells were grown on cover slips for 48 hrs at 37⁰C in RPMI Complete media in 
5% CO2 , incubated in a 90% media + 10% phage solution overnight (for each phage 
peptide) at 4⁰C, and washed thrice with PBS (1X) between each step. All steps were 
performed at RT. Cells were fixed for 20 minutes in a 4% PFA solution (4% 
paraformaldehyde in PBS (1X)), washed, blocked for 20 minutes in PBT (PBS (1X) + 
1% BSA + 0.1% Triton X-100), washed, incubated with phage for 20 minutes, washed, 
incubated with 1⁰(anti-M13) 1:1000 for phage peptides, washed, incubated with 
2⁰(GAM/Cy3) 1:2000, washed, incubated with Alexa Fluor 488 Phalloidin 1:1000 and 
Hoescht 33342 1:5000 for 20 minutes, washed, and mounted on slides for confocal 
microscopy. A no-phage negative control was included for antibody binding specificity. 
Cells were imaged on a Carl Zeiss Axio Observer Z1 Spinning Disc Confocal 
Microscope. 
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Negative Control Cell Line THP-1 Cells - Membrane Receptor Binding and Cellular 
Uptake of Phage Display Derived Peptides 
Cells were grown in flasks for 48 hrs at 37⁰C in RPMI Complete media in 5% 
CO2 , incubated in a 90% media + 10% phage solution overnight (for each phage peptide) 
at 4⁰C, and washed thrice with PBS (1X) between each step. Cells were transferred to 15 
ml centrifuge tubes and gently centrifuged and softly pelleted between each step. All 
steps were performed at RT. Cells were fixed for 20 minutes in a 4% PFA solution (4% 
paraformaldehyde in PBS (1X)), washed, blocked for 20 minutes in PBT (PBS (1X) + 
1% BSA + 0.1% Triton X-100), washed, incubated with phage for 20 minutes, washed, 
incubated with 1⁰(anti-M13) 1:1000 for phage peptides, washed, incubated with 
2⁰(GAM/Cy3) 1:2000, washed, incubated with Alexa Fluor 488 Phalloidin 1:1000 and 
Hoescht 33342 1:5000 for 20 minutes, and washed. Cells were resuspended in mounting 
media, transferred to cover slips, and mounted on slides for confocal microscopy. No 
negative controls were included. Cells were imaged on a Carl Zeiss Axio Observer Z1 
Spinning Disc Confocal Microscope. 
The Effect of Phage Peptide Incubation and Length of Initial Growth Cycle on the 
Viability of U87-MG Cells 
The populations consisted of 1 well each containing 100,000 cells. Cells were 
grown for 24 hrs at 37⁰C in 90% MEM (Fisher Scientific) + 10% FBS in 5% CO2 and 
then incubated in a 90% media + 10% phage solution (for each phage peptide) for 
another 48 hrs. Control wells included the Standard which only contained media and the 
PBS (1X) well that had 90% media + 10% PBS (1X). Cells were trypsinized and 
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harvested. Live/Dead staining was performed with a hemocytometer and Trypan Blue. 
The average of 10 counts was used for statistical analysis, t-test with α = 0.05. All 
analysis were based on comparison with the Standard (t Critical one-tail = 1.833 and t 
Critical two-tail = 2.262). 
The Effect of Phage Peptide Incubation and Length of Initial Growth Cycle on the 
Viability of U87-MG Cells 
 The populations consisted of 4 wells, each containing 84,000 cells. Cells were 
grown for 24 hrs at 37⁰C in 90% MEM + 10% FBS in 5% CO2 and then incubated in a 
90% media + 10% phage solution (for each phage peptide) for another 48 hrs. Control 
wells included the Standard which only contained media and the PBS (1X) well that had 
90% media + 10% PBS (1X). Cells were trypsinized and harvested. Live/Dead staining 
was performed with a hemocytometer and Trypan Blue. The average of 10 counts was 
used for statistical analysis, t-test with α = 0.05. All analysis were based on comparison 
with the Standard (t Critical one-tail = 1.833 and t Critical two-tail = 2.262). 
The Effect of Phage Peptide Incubation on the Cell Proliferation of U87-MG Cells 
The populations consisted of 6 wells each containing 25,000 cells. Cells were 
grown for 48 hrs at 37⁰C in 90% MEM + 10% FBS in 5% CO2 and then incubated in a 
90% media + 10% phage solution (for each phage peptide) for another 48 hrs. The 
negative control population received no phage exposure. A Vybrant® MTT assay (Fisher 
Scientific) was performed according to the manufacturers Quick Protocol Option. Briefly, 
10 µL of the 12 mM MTT stock solution was added to each well and incubated at 37°C 
for 4 hours. Then 85 µl of media was removed, 50 µL of DMSO was added to each well 
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and mixed thoroughly, cells were incubated at 37°C for 10 minutes, mixed again and 
absorbance was read on a BioTek microplate reader at 540 nm instead of 570 nm and the 
values were exported into an Excel spreadsheet. All analysis were based on comparison 
with the Standard (t Critical one-tail = 2.920 and t Critical two-tail = 4.302) (α = 0.05). 
Whole-Cell ELISA Confirmation of U87-MG Cell Membrane Binding by Phage 
Peptides Using an HRP Conjugated Anti-M13 Antibody with a TMB Substrate and 
STOP-450 Solution 
The populations consisted of 6 wells each containing 25,000 cells. Cells were 
grown for 48 hrs at 37⁰C in 90% MEM + 10% FBS in 5% CO2 and washed thrice with 
PBS (1X) between each step. Cells were blocked for 2 hrs with 1% BSA, washed, and 
incubated in a 90% media + 10% (phage/0.5% BSA) solution (for each phage peptide) 
for 4 hrs at RT (a no-phage negative control was included with 0.5% BSA). Wells were 
washed, incubated with anti-M13 HRP conjugated mAb (GE Healthcare) 1:2500 for 1 hr, 
washed, incubated with the TMB substrate (Abcam) for 1 hr, and allowed to develop 
color for 45 minutes. The acidic 450 nm STOP Solution (Abcam) was added to stop the 
enzymatic reaction. Absorbance was read at 450 nm on a BioTek microplate reader and 
the values were exported into an Excel spreadsheet. All phage peptide results were 
compared to the no-phage negative control (α = 0.05) (t Critical one-tail = 2.920 and t 
Critical two-tail = 4.302). 
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U87-MG Cells - Confirmation of Co-Localization of Phage Display Derived Peptides 
and the Known ACKR3/CXCR7 Antibody, Anti-RDC1 
The populations consisted of U87-MG cells grown on cover slips. Experimental 
Cells were grown for 48 hrs at 37⁰C in 90% MEM + 10% FBS in 5% CO2 and then 
incubated in a 90% media + 10% phage solution (for each phage peptide) for 4 hours at 
RT. Cells were washed thrice with PBS (1X) between each step. All steps were 
performed at RT. Cells were fixed for 20 minutes in a 4% PFA solution (4% 
paraformaldehyde in PBS (1X)), washed, blocked for 20 minutes in PBT (PBS (1X) + 
1% BSA + 0.1% Triton X-100), washed, incubated with phage for 20 minutes, washed, 
incubated with 1⁰(anti-M13) 1:1000 for phage peptides or 1⁰(anti-RDC1) for the 
ACKR3/CXCR7 receptor 1:1000, washed, incubated with 2⁰(DAM/Alexa488) 1:2000 
for phage peptides or 2⁰(GAR/Cy3) for the ACKR3/CXCR7 receptor 1:2000, washed, 
incubated with Hoescht 33342 1:5000 for 20 minutes, washed, and mounted on slides for 
confocal microscopy. No-phage and no-1⁰ antibody negative controls were included for 
1⁰ and 2⁰ antibody binding specificity. Cells were imaged on a Carl Zeiss Axio Observer 
Z1 Spinning Disc Confocal Microscope. 
Quantifying the Level of ACKR3/CXCR7 Activation Using a PathHunter β-Arrestin 
Assay (DiscoverX) with the Phage Peptides, the Endogenous Ligand SDF1α, and 
CHO-K1 Modified Cells 
A 12-point dose response curve was performed according to the manufacturer’s 
instructions. The CHO-K1 cells were seeded at 10,000 cells per well on a 96-well plate 
with AssayComplete Cell Plating Reagent and grown for 48hrs at 37⁰C. The phage were 
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started at a concentration of 10
18
 PFU`s and diluted 10 times sequentially by 1/3 to a final 
concentration of 1.69 * 10
13
 PFU`s. The SDF1α ligand was started at a concentration of 
20 µM and also diluted 10 times sequentially by 1/3 to a final concentration of 3.39 pM. 
There were two wells used per treatment for each dilution for eleven wells. A no-agonist 
(SDF1α) negative control and no-phage negative control wells were used for well twelve. 
The cells were incubated with the phage peptides or the agonist, SDF1α, for 90 minutes 
at 37⁰C. Luminescence was read on a BioTek microplate reader and the RLU values were 
exported into an Excel spreadsheet. The rough approximation of the EC50 was calculated 
using the average value for all agonist treatments and then interpolating the molar value 
using the slope between the data points on either side of the average value, (M=Y2-
Y1/X2-X1) where X1≠X2. 
Results 
 
The Effect of Phage Peptide Incubation on the Viability of a Small Population of 
MCF-7 Cells 
The Live/Dead staining was performed and no statistical difference in viability 
was observed between the standard MEDIA treatment and the other treatments (α = 
0.05). The average live cell values for the different treatments were: MEDIA 82.24%, 
PBS (1X) 85.00%, P-20 81.82%, P-9 80.67%, and P-3 83.19% as seen in Figure (11).   
The Effect of Phage Peptide Incubation on the Viability of a Large Population of 
MCF-7 Cells 
The Live/Dead staining was performed and no statistical difference in viability 
was observed between the standard MEDIA treatment and the other treatments (α = 
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0.05). The average live cell values for the different treatments were: MEDIA 87.50%, 
PBS (1X) 83.69%, P-20 85.53%, P-9 84.17%, and P-3 84.56% as seen in Figure (12). 
The Effect of Phage Peptide Incubation on the Cell Proliferation of MCF-7 Cells 
An MTT assay was performed and no statistical difference in viability was 
observed between the standard MEDIA treatment and the other treatments (α = 0.05). 
The values for the different treatments were: MEDIA 0.398, PBS (1X) 0.386, P-20 0.383, 
P-9 0.387, and P-3 0.385 as seen in Figure (13). 
Whole-Cell ELISA Confirmation of MCF-7 Cell Membrane Binding by Phage 
Peptides Using an HRP Conjugated Anti-M13 Antibody with a TMB Substrate and 
STOP-450 Solution 
All phage peptide results were statistically significant compared to the no-phage 
negative control (α = 0.05) (t Critical one-tail = 2.920 and t Critical two-tail = 4.302). The 
values for the different treatments were: Negative Control 0.073, P-20 0.254, P-9 0.256, 
and P-3 0.257 as seen in Figure (14). The experimental values were approximately 3.5 
times higher than the negative control value. 
MCF-7 Cells - Membrane Receptor Binding and Cellular Uptake of Phage Display 
Derived Peptides 
The fluorescent dyes used were: [Hoechst-BLUE for Nucleus, Alexa488-GREEN 
for actin, 2⁰(GAM/Cy3-RED) - 1⁰(anti-M13) for Phage Peptides]. Negative controls 
were included and confirmed binding specificity. Membrane binding and cellular uptake 
of all three phage peptides was confirmed by the areas of fluorescence overlap indicated 
by YELLOW (Membrane) and PURPLE (Nucleus) as seen in Figure (15). 
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Negative Control Cell Line THP-1 Cells - Membrane Receptor Binding and Cellular 
Uptake of Phage Display Derived Peptides 
The fluorescent dyes used were: [Hoechst-BLUE for Nucleus, Alexa488-GREEN 
for actin, 2⁰(GAM/Cy3-RED) - 1⁰(anti-M13) for Phage Peptides]. Any areas of location 
overlap would have been indicated by YELLOW (Membrane) and PURPLE (Nucleus). 
No phage binding was observed and therefore no negative controls were tested as seen in 
Figure (16).  
The Effect of Phage Peptide Incubation and Length of Initial Growth Cycle (24 hrs) 
on the Viability of U87-MG Cells 
The Live/Dead staining was performed and no statistical difference in viability 
was observed between the standard MEDIA treatment and the other treatments (α = 
0.05). The average live cell values for the different treatments were: MEDIA 90.00%, 
PBS (1X) 87.80%, P-20 92.50%, P-9 86.84%, and P-3 87.18% as seen in Figure (17).  
The Effect of Phage Peptide Incubation and Length of Initial Growth Cycle (48 hrs) 
on the Viability of U87-MG Cells 
The Live/Dead staining was performed and no statistical difference in viability 
was observed between the standard MEDIA treatment and the other treatments (α = 
0.05). The values for the different treatments were: MEDIA 92.57%, PBS (1X) 91.42%, 
P-20 91.67%, P-9 90.46%, and P-3 91.10% as seen in Figure (18). 
The Effect of Phage Peptide Incubation on the Cell Proliferation of U87-MG Cells 
An MTT assay was performed and no statistical difference in viability was 
observed between the standard MEDIA treatment and the other treatments (α = 0.05). 
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The average live cell values for the different treatments were: MEDIA 0.367, BSA 0.357, 
P-20 0.355, P-9 0.362, and P-3 0.361 as seen in Figure (19). 
Whole-Cell ELISA Confirmation of U87-MG Cell Membrane Binding by Phage 
Peptides Using an HRP Conjugated Anti-M13 Antibody with a TMB Substrate and 
STOP-450 Solution 
All phage peptide results were statistically significant compared to the no-phage 
negative control (α = 0.05) (t Critical one-tail = 2.920 and t Critical two-tail = 4.302). The 
values for the different treatments were: Negative Control 0.110, P-20 0.330, P-9 0.328, 
and P-3 0.332 as seen in Figure (20). The experimental values were approximately 3 
times higher than the negative control value. 
U87-MG Cells - Confirmation of Co-Localization of Phage Display Derived Peptides 
and the Known ACKR3/CXCR7 Antibody, Anti-RDC1 
The fluorescent dyes used were: [Hoechst-BLUE for Nucleus, 2⁰(GAR/Cy3-
RED) - 1⁰(anti-RDC1) for ACKR3/CXCR7 receptor, 2⁰(DAM/Alexa488-GREEN) - 
1⁰(anti-M13) for Phage Peptides]. All three phage peptides were shown to bind the 
extracellular membrane and be internalized by the U87-MG cells as seen in Figure (21-
Continued). Negative control experiments verified the specificity of the 1⁰ and 2⁰ 
antibodies used in these experiments as seen in Figures (21A and 21B). The areas of 
colocalization at the extracellular membrane and in the cytoplasm are indicated by the 
YELLOW overlap (RDC1-RED + Phage Peptide-GREEN). Areas of intracellular 
colocalization in and around the nucleus are indicated by the GREEN + BLUE overlap as 
seen in Figure (21B). 
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Quantifying the Level of ACKR3/CXCR7 Activation Using a PathHunter β-Arrestin 
Assay (DiscoverX) with the Phage Peptides, the Endogenous Ligand SDF1α, and 
CHO-K1 Modified Cells 
A 12-point dose response curve was performed according to the manufacturer’s 
instructions. The Phage Peptides showed no effect compared to SDF1α as seen in Figure 
(22). The endogenous ligand SDF1α activated the receptor as expected. Activation was 
starting at dilution #5, ~915 pM, and began to plateau at dilution #10, 222 nM. The 
average value for the agonist treatments was 5,579 and this fell between data points #7 
and #8. Data point #7 had an average value of 2,776 at a concentration of 8.23 x 10E-9 
[M] and Data point #8 had an average value of 6,445 at 2.47 x 10E-8 [M]. The EC50 was 
roughly approximated at 20.89 nM and was slightly higher than but comparable to the 
manufacturer’s stated EC50 of 3.5 nM. 
Discussion 
 
The ability to target cancer cells specifically allows for the delivery of 
chemotherapeutics, anti-cancer compounds, or contrast agents for imaging directly to the 
tumor region. These experiments have shown that the phage display peptides recovered 
from our previous experiments utilizing a synthesized portion of the N-terminus region of 
ACKR3/ CXCR7 were viable candidates for targeting MCF-7 breast cancer cells and 
U87-MG glioblastoma (GBM) cells [
67
]. The three peptides, P-20, P-9, and P-3 were 
shown to have no effect on the viability or proliferation of MCF-7 or U87-MG cells. 
Additionally, the peptides were observed to significantly bind these same cell lines using 
a whole-cell ELISA protocol. The ability of these cancer cell types to bind and internalize 
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the peptides was confirmed using confocal microscopy. The affinity of these peptides for 
the ACKR3/CXCR7 receptor was verified using a co-localization assay and the known 
anti-ACKR3/CXCR7 mAb RDC1.  
The final piece of the peptide cell interaction puzzle was to quantify whether or 
not the peptides would activate the receptor upon binding. Utilizing a luminescent β-
arrestin activation assay and a 12-point dose response curve, the peptides were shown to 
have no effect on the recruitment of β-arrestin and did not activate the receptor upon 
binding. Activation of the receptor was verified after exposure to the endogenous ligand 
SDF1α. The results of the SDF1α assay were validated when compared side-by-side with 
the published results from the manufacturer DiscoverX. 
In conclusion, the three phage display derived peptides; P-20, P-9, and P-3 were 
shown to be viable candidates to be used as targeting moieties for ACKR3/CXCR7. The 
peptides showed no effect on cell viability or proliferation when used against MCF-7 
breast cancer cells and U87-MG glioblastoma (GBM) cells. The peptides did bind the cell 
membrane of these same cell lines and were taken up intracellularly as seen in the whole-
cell ELISA and confocal microscopy experiments. Lastly, the peptides had no effect on 
the activation of the receptor unlike the endogenous ligand CXCL12/SDF1as confirmed 
in the β-arrestin recruitment assay. These results show conclusively that our phage 
display protocol used against a synthesized portion of the N-terminus region of 
ACKR3/CXCR7 identified at least three valid candidates for targeting breast cancer and 
brain cancer cells. 
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CHAPTER IV 
 
CONCLUSIONS AND FUTURE APPLICATIONS 
 
 
In summary, we have identified three heptameric peptide sequences, P-20, P-9, 
and P-3, which bind a synthesized portion of the N-terminus region of ACKR3/CXCR7, 
have different physical and chemical properties, and are predicted to mimic three 
different regions of the endogenous ligand SDF1/CXCL12. These same three peptides 
were shown to have no effect on the viability or proliferation of MCF-7 or U87-MG cells. 
Additionally, the peptides were observed to significantly bind these same cell lines using 
a whole-cell ELISA protocol. The ability of these cancer cell types to bind and internalize 
the peptides was confirmed using confocal microscopy. The peptides were shown to bind 
the MCF-7 cells that express ACKR3/CXCR7 but not CXCR4. The peptides were also 
shown to have no affinity for THP-1 cells that do not express ACKR3/CXCR7 but do 
express CXCR4. The affinity of these peptides for the ACKR3/CXCR7 receptor was 
verified using a co-localization assay and the known anti-ACKR3/CXCR7 mAb RDC1.  
The last bit of information needed was to quantify whether or not the peptides 
would activate the receptor upon binding. The peptides were shown to have no effect on 
the recruitment of β-arrestin and did not activate the receptor upon binding. Activation of 
the ACKR3/CXCR7 receptor was validated via exposure to its natural ligand SDF1α. The 
inability to activate the receptor is an integral part of our desired targeting moiety system. 
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Based on the data presented here, the three recovered peptides P-20, P-9, and P-3 are 
specific for the N-terminus of ACKR3/CXCR7. 
The secondary component of the overall system, the liposome was also 
successfully completed. Liposomes comprised of a C-70 derivative (ALM) and a 
naturally occurring lipid (egg-PC) was consistently synthesized at the desired size of ~99 
nm +/- ~12 nm [
67
]. Many of the characteristics of liposomes are controllable and can be 
modified for the desired effect. The use of cholesterol has been shown to be a required 
component for the uptake of liposomes into peripheral neurons and glial cells [
167
]. 
Conjugation of the discovered targeting moieties to the liposomal vehicle could be easily 
accomplished using cholesterol and this would provide the ability to deliver 
chemotherapeutics, contrast agents, genetic material, and other compounds directly to the 
targeted cells [
147
].  
The cholesterol molecules themselves could be modified to change the surface 
charge of the liposome. A cholesterol hemisuccinate derivate (CHEMS) imparted a 
negative charge, a lysine-based cholesterol (CHYLS) derivative gave the system a 
positive charge, and the PEGylated cholesterol (Chol-PEG) provided no charge. All of 
their liposomes were in the 104 nm to 163 nm range. The anionic liposomes showed the 
greatest interaction with the cell membrane most likely due to electrostatic attractions 
between the positively charged liposome membrane and the negatively charged cancer 
cell membranes [
168
]. The inclusion of increasing concentrations of cholesterol in the 
lipid bilayer of liposomes has been shown to make them more rigid and susceptible to 
triggered release of their contents by induction of a magnetic field. This bit of 
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information is useful because these liposomes contained no metal particles and many 
cancers are imaged with MRI [
169
].  
The targeting moieties could instead be conjugated to the polyethylene glycol–
dioleoyl phosphatidylethanolamine (PEG–DOPE) amphiphilic copolymer and 
incorporated directly into the liposomes membrane. This method not only used PEG to 
escape the RES but it also used a short eight amino acid long peptide, similar to our seven 
amino acid long peptide, as its targeting moiety for breast cancer cells [
10
].  Another 
method to alter liposome characteristics is to change the pH of the solutions being used. 
Doxorubicin has been shown to have a positive charge below pH8 and this changed the 
loading capacity of the liposomes based on their charge, positive or negative [
13
].  
Using a hydration medium with a pH of 4, the positively charged liposomes were 
limited in their ability to sequester Doxorubicin in the aqueous phase and into its core 
region. Due to this limitation, the negatively charged liposomes incorporated more than 
three times as much doxorubicin into its core region. The negatively charged liposomes 
only showed a modest 20% increase in loading capacity when the doxorubicin was 
dissolved in the methanol-chloroform solvent [
13
]. Thus it is possible to alter the amount 
of compound load based upon the pH of the solution used in the hydration buffers.  
Finally, liposomes can be made sensitive to ultrasound stimulation, sonosensitive, 
by incorporating the proper lipid into the bilayer. Liposomes synthesized at 98 nm that 
have dioleoyl phosphatidylethanolamine (DOPE) in the membrane have been shown to 
have enhanced sonosensitivity [
170
]. Based on all of the information gathered about 
liposomal configurations, the optimum set up would be comprised of four components: 
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dioleoyl phosphatidylethanolamine (DOPE), the functionalized C70 derivative 
Amphiphilic Liposomal Malonylfullerene[70] (ALM), PEGylated-
distearoylphosphatidylethanolamine (DSPE-PEG 2000), and cholesterol in a roughly 
25:27:8:40 mol%. This particular configuration would allow for modifications to be made 
to the surface charge of the liposome, control loading capacities with pH, scavenge ROS 
with the empty cage fullerene derivative, and allow for the controlled release of 
encapsulated compounds via ultrasound and magnetic exposure. Combining our 
recovered peptide sequences with this liposomal configuration has the potential to 
provide a new mechanism for the targeting of multiple forms of cancer and chronically 
infected cells. This would accomplish our goal of increasing the efficacy of current 
treatment regimens, while greatly reducing the pain and suffering caused to patients by 
many of today`s standard procedures. 
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Figure 1. CXCR4 and ACKR3/CXCR7 40 Amino Acid N-Terminus Comparison 
and Epitope Mapping. The locations of posttranslationally modified residues are 
identified with a Red*, Yellow*, or Green* based on residue type. The locations of 
predicted epitope sites are identified by name (Bepipred, Kolaskar, or Emini) and the 
associated residue locations. The locations of residues identical to both receptors are 
linked together with a Blue line (i.e. M1-M1, Y7-Y8, etc.). Residues are colored based on 
the amino acid (A.A.) legend in the figure and the 20 ACKR3/CXCR7 residues chosen 
(F6-D25) for experimentation are outlined in the boxed region. The location of the β- 
sheet fold for each N-terminus is listed. 
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Figure 2. Selection of the Scrambled (Scr) Control Sequence for ELISA Analysis. 
The selected control sequence was labeled “Scrambled”. Examples 1, 2, and 3 are 
representative of rejected scrambled sequence candidates due to their similarities with the 
sections of the ACKR3/CXCR7 and CXCR4 sequences listed below them. The symbol * 
= similarity to ACKR3/CXCR7 sequence and ** = similarity to CXCR4 sequence.
 
Scrambled:  SWESFPNDCSYGDNDFSPIS Legend for amino acid 
characterization:                                       
Amino Acid Groups: 
aromatics are underlined 
Positive Charge (+): R (Arg), 
H (His), K (Lys) 
 
Negative Charge (-): D (Asp), 
E (Glu) 
 
Polar Uncharged: S (Ser), T 
(Thr), N (Asn), Q (Gln) 
 
Special Cases: C (Cys), G 
(Gly), and P (Pro) 
 
Hydrophobic: A (Ala), V (Val), 
I (Ile), L (Leu), M (Met), F 
(Phe), Y (Tyr), W (Trp) 
 
Example 1:  SSYGSIPNFSD NEDFSPCWD 
                                *GNFSD/ TEEM** 
Example 2:  NPWSIFSYEDDCG NSSSDFP 
           **YTEEMG/ NSSD* 
Example 3:  SFPDCPENSGWDFNSSDISY   
       *NSSD/DISW* 
CXCR7 seq:  FDYSEPGNFSDISWPCNSSD  
CXCR4 seq:  IYTSDNYTEEMGSGDYDSMK 
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Figure 3. Phage Peptides Insert Coding Sequence Comparison and Predicted Physical and Chemical Properties of the 
Putative CXCR7 Binding Phages. The DNA coding sequence for each 7 amino acid insert sequence is listed as well as the 
predicted values for the Isoelectric point (pI), Estimated Half-Life in reticulocytes, Instability index, Aliphatic index, and 
GRAVY index of each insert sequence. DNA coding sequences reveal no cross contamination. 
 
Id # P or 
C-__ 
Peptide 
sequence 
DNA sequence Isoelectric 
point (pI) 
Estimated  
half-life 
Instability 
Index 
Aliphatic 
Index 
GRAVY 
P-16 GPLSRPG GGTCCTCTTTCTCGTCCTGGT 9.75 30 hrs 63.60 55.71 -0.786 
P-13 APLSRPG GCTCCGCTGTCTCGGCCTGGT 9.79 4.4 hrs 91.11 70.00 -0.471 
P-19 APLSRPG GCTCCGCTGTCTCCTCCTGGG 9.79 4.4 hrs 91.11 70.00 -0.471 
P-18 APLSRRG GCTCCGCTTTCTCGTCGTGGT 12.00 4.4 hrs 133.30 70.00 -0.886 
P-20 APLPRPG GCTCCTCTTCCTCGTCCTGGT 9.79 4.4 hrs 80.34 70.00 -0.586 
P-14 APLSPPG GCTCCGCTGTCTCCTCCTGGG 5.57 4.4 hrs 126.37 70.00 -0.057 
P-15 APLSPPG GCTCCTCTTTCTCCTCCTGGT 5.57 4.4 hrs 126.37 70.00 -0.057 
P-21 APLSPPG GCTCCTCTTTCTCCTCCTGGG 5.57 4.4 hrs 126.37 70.00 -0.057 
P-22 APLSPPG GCTCCTCTGTCTCCTCCTGGG 5.57 4.4 hrs 126.37 70.00 -0.057 
P-23 APLSPPG GCTCCTCTTTCTCCTCCTGGT 5.57 4.4 hrs 126.37 70.00 -0.057 
P-24 APLSPPG GCTCCGCTTTCTCCTCCTGGG 5.57 4.4 hrs 126.37 70.00 -0.057 
P-17 HPLMRRG CATCCGCTGATGCGGCGTGGT 12.00 3.5 hrs 63.39 55.71 -1.214 
P-08 HPLIVLE CATCCGCTGATTGTTCTTGAG 5.24 3.5 hrs -7.67 208.57 1.143 
P-C5 AVLRTSP GCTGTGCTTCGGACTTCTCCG 9.79 4.4 hrs 98.86 111.43 0.314 
P-10 APSPMIW GCGCCTTCGCCTATGATTTGG 5.57 4.4 hrs 115.60 70.00 0.471 
P-C4 HSLELMP CATAGTCTTGAGCTTATGCCG 5.24 3.5 hrs 71.34 11.43 0.057 
P-11 RLPAFLH CGTCTTCCTGCTTTTCTGCAT 9.76 1 hr 63.60 125.71 0.414 
P-01 LMPARYH CTTATGCCTGCGCGTTATCAT 8.75 5.5 hrs 105.71 70.00 -0.443 
P-C6 HLWLTPP CATTTGTGGTTGACGCCGCCT 6.74 3.5 hrs 87.54 111.43 -0.057 
P-02 TYASDRS ACGTATGCTTCTGATCGTAGT 5.50 7.2 hrs 94.40 14.29 -1.400 
P-05 QYATPSA CAGTATGCGACGCCGAGTGCG 5.52 0.8 hrs 59.14 28.57 -0.614 
P-03 QMAQWPP CAGATGGCGCAGTGGCCTCCG 5.52 0.8 hrs 53.71 14.29 -1.057 
P-06 SWNMWSP CAGTATGCGACGCCGAGTGCG 5.24 1.9 hrs 88.97 0.00 -0.943 
P-C2 HWGMWSY CATTGGGGGATGTGGAGTTAT 6.74 3.5 hrs -10.36 0.00 -0.800 
P-07 VNSAWTY GTGAATTCGGCGTGGACGTAT 5.49 100 hrs -12.90 55.71 -0.171 
P-04 TTTWHLK ACTACGACGTGGCATCTTAAG 8.44 7.2 hrs 8.80 55.71 -0.900 
P-C3 NQSAVLP AATCAGTCTGCTGTTTTGCCG 5.52 1.4 hrs 88.09 111.43 0.057 
P-09 DSHTPQR GATTCGCATACTCCGCAGAGG 6.74 1.1 hrs 52.83 0.00 -2.543 
P-C1 GHWTRFA GGTCATTGGACGAGGTTTGCG 9.76 30 hrs -17.01 14.29 -0.729 
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Figure 4. ClustalW Predicted Regions of Similarity for Phage Peptides with the Endogenous Ligand, SDF1. ClustalW 
analyses comparing the identified phage peptide insert sequences to the protein sequence of SDF1.The recovered putative 
ACKR3/CXCR7 targeting peptides fell into three clusters. None of the peptides were predicted to mimic the first 20 residues 
of SDF1.
Activation(Act), Receptor(Rec)/Heparin(Hep) Binding:              22-23 Act,         29-33 Rec/Hep ,           39-41 Rec ,     41-51 Hep , 48-50 Rec, 60---------------70 Rec  
SDF1    2⁰ structure: T=Turn, β=β-strand, H=Helix   T (24-26), β(27-29), β(31-34),                                     β(36-38), H(41-43), β(44-49), T(53-55), β(59-63), T(64-66), β(69-72), H(79-86)
SDF1 sequence with ClustalW alignment position GKPVS LSYRC PCRFF ESHVA RANVK HLKIL NTPNC ALQIV ARLKN NNRQV CIDPK LKWIQ EYLEK ALNKR FKM
Peptide Id Peptide Seq ClustalW Seq 21-25 26-30 31-35 36-40 41-45 46-50 51-55 56-60 61-65 66-70 71-75 76-80 81-85 86-90 91-93
P_16 GPLSRPG GPVSRPC 21, 23-25 29 31,32
P_13 APLSRPG CPLNTPN 30 31 50 51-54
P_18 APLSRRG TPVARKN 52,53 60 61,62,64,65
P_20 APLPRPG KPVPRPN 22-24 31, 33 53,54
P_24 APLSPPG CPLNTPN 30 31 50 51-54
P_17 HPLMRRG DPYLEKA 73,74 82-85 86
P_8 HPLIVLE TPLQIVA 52,53 57-60 61
C_5 AVLRTSP KILNTPP 48-50 51-53 74
P_10 APSPMIW TPDPLKW 52,53 73,74 76-78
C_4 HSLELMP KHLKILP 45 46-50 53
P_11 RLPAFLH RCPCFFE 29,30 31,32,34,35 36
P_1 LMPARYH LCPCRFH 26,30 31-34 38
C_6 HLWLTPP KLWIQEY 75 76,78-80 81,82
P_2 TYASDRS SYRCERA 27-30 36 41,42
P_5 QYATPSA SYRCPCR 27-30 31-33
P_3 QMAQWPP QVCKWIQ 69,70 71 77-80
P_6 SWNMWSP KWQEYLE 77,78,80 81-84
C_2 HWGMWSY KWIQEYL 77-80 81-83
P_7 VNSAWTY IDPKWIY 72-74 77-79 82
P_4 TTTWHLK KLKWYLE 75 76-78 82-84
C_3 NQSAVLP NRQVCIP 67-70 71,72,74
P_9 DSHTPQR ESHTPAR 36-38 52,53 61,62
C_1 GHWTRFA DKWIRFK 73 77-79 90 91,92
Number of peptides predicted to simulate each region 2 7 7 4 2 4 8 2 3 2 9 8 6 2 1
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Figure 5. Normalized ELISA Results: Phage Peptide Binding to CXCR7 Target or 
the Scrambled (Scr) Negative Control Peptide. The Level of Significance used was 5% 
(Alpha α = 0.05). The threshold cutoff values used were: * t-test Critical one-tail = 
2.91998558 and ** t-test Critical two-tail = 4.30265273. Vertical error bars in both 
directions were set based on the Standard Error Margin (SEM). Phage P-2 was the first 
peptide to exceed the 2.92 (α = 0.05) threshold value for significance in the experimental 
versus blank control series. Phage P-20 had the greatest affinity for CXCR7. 
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Figure 6. 3D Molecular Model of the ACKR3/CXCR7 N-Terminus (F6-D25). 3D 
model of the ACKR3/CXCR7 N-terminus F6-D25 (FDYSEPGNFSDISWPCNSSD) in 
CPK BALL & STICK mode overlaid on top of the corresponding CXCR4 N-terminus I6-
K25 (IYTSDNYTEEMGSGDYDSMK) in PINK thin-tube mode. The residue 
phenylalanine-6 (F6) of the N-terminus of ACKR3/CXCR7 is highlighted in GREEN. 
The serine residues identical to both the ACKR3/CXCR7 and CXCR4 sequences, S9, 
S18, and S23, are highlighted in YELLOW. 
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Figure 7. 3D Model Representing the Physical Location of Ligand Residues Similar 
to Peptide P-20. Amino acids from the endogenous ligand SDF1/CXCL12 
(K
22
P
23
V
24
P
31
R
33
P
53
N
54
) that were identified as the most similar to the sequence of 
Peptide P-20 (APLPRPG) are shown in Space-Fill mode interacting with the CXCR7 N-
terminus (F6-D25) sequence model (CPK BALL & STICK mode). The residue 
phenylalanine-6 (F6) of the N-terminus of ACKR3/CXCR7 is highlighted in GREEN. 
The serine residues identical to both the ACKR3/CXCR7 and CXCR4 sequences, S9, 
S18, and S23, are highlighted in YELLOW. 
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Figure 8. 3D Model Representing the Physical Location of Ligand Residues Similar 
to Peptide P-9. Amino acids from the endogenous ligand SDF1/CXCL12 
(E36S37H38T52P53A61R62) that were identified as the most similar to the sequence of 
Peptide P-9 (DSHTPQR) are shown in Space-Fill mode interacting with the CXCR7 N-
terminus (F6-D25) sequence model (CPK BALL & STICK mode). The residue 
phenylalanine-6 (F6) of the N-terminus of ACKR3/CXCR7 is highlighted in GREEN. 
The serine residues identical to both the ACKR3/CXCR7 and CXCR4 sequences, S9, 
S18, and S23, are highlighted in YELLOW. 
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Figure 9. 3D Model Representing the Physical Location of Ligand Residues Similar 
to Peptide P-3. Amino acids from the endogenous ligand SDF1/CXCL12 
(Q69V70C71K77W78I79Q80) that were identified as the most similar to the sequence of 
Peptide P-3 (QMAQWPP) are shown in Space-Fill mode interacting with the CXCR7 N-
terminus (F6-D25) sequence model (CPK BALL & STICK mode). The residue 
phenylalanine-6 (F6) of the N-terminus of ACKR3/CXCR7 is highlighted in GREEN. 
The serine residues identical to both the ACKR3/CXCR7 and CXCR4 sequences, S9, 
S18, and S23, are highlighted in YELLOW. 
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Figure 10. 100 nm Liposome Synthesis Using C-70 Derivative (ALM) and Egg-PC 
(1:2). ALM and egg-PC were dissolved in diethyl-ether in a round bottom flask 
suspended in an ice-water bath and sparged with Nitrogen to form a lipid film. The film 
was rehydrated with PBS (1X) for two hours at RT. The rehydrated PBS (1X) /ALM/egg-
pc solution and extruder were maintained at 29°C. The solution was sequentially pushed 
through a 400nm, 200nm, and finally 100nm filter. The particle size and zeta potential 
were determined using a MicrotrakZetatrac. 
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Figure 11. The Effect of Phage Peptide Incubation on the Viability of a Small 
Population of MCF-7 Cells. The populations consisted of 3 wells each containing 5,000 
cells. Cells were grown for 48 hrs and then incubated in a 10% phage/PBS (1X) solution 
for another 48 hrs. Standard well received only media and PBS well received PBS (1X) 
instead of phage peptide. Live/Dead staining was performed with Trypan Blue and no 
statistical difference in viability was observed (α = 0.05). 
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Figure 12. The Effect of Phage Peptide Incubation on the Viability of a Large 
Population of MCF-7 Cells. The populations consisted of 1 well each containing 
100,000 cells. Cells were grown for 48 hrs and then incubated in a 10% phage/PBS (1X) 
solution for another 48 hrs. Standard well received only media and PBS well received 
PBS (1X) instead of phage peptide. Live/Dead staining was performed with Trypan Blue 
and no statistical difference in viability was observed (α = 0.05). 
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Figure 13. The Effect of Phage Peptide Incubation on the Cell Proliferation of MCF-
7 Cells. The populations consisted of 6 wells each containing 25,000 cells. Cells were 
grown for 48 hrs and then incubated in a 10% phage/BSA (0.5%) solution for another 48 
hrs. Standard well received only media and BSA well received BSA (0.5%) instead of 
phage peptide. An MTT assay was performed and no statistical difference in viability was 
observed (α = 0.05). 
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Figure 14. Whole-Cell ELISA Confirmation of MCF-7 Cell Membrane Binding by 
Phage Peptides Using an HRP Conjugated Anti-M13 Antibody with a TMB 
Substrate and STOP-450 Solution. The populations consisted of 6 wells each 
containing 25,000 cells. Cells were grown for 48 hrs at 37⁰C and then incubated in a 10% 
phage/PBS (1X) solution for 2 hrs at 4⁰C. All phage peptide results were statistically 
significant compared to the no-phage negative control (α = 0.05).   
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Figure 15. MCF-7 Cells - Membrane Receptor Binding and Cellular Uptake of 
Phage Display Derived Peptides. The fluorescent dyes used were: [Hoechst-BLUE for 
Nucleus, Alexa488-GREEN for actin, 2⁰(GAM/Cy3-RED) - 1⁰(anti-M13) for Phage 
Peptides]. Areas of location overlap are indicated by YELLOW (Membrane) and 
PURPLE (Nucleus). 
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Figure 16. Negative Control Cell Line THP-1 Cells - Membrane Receptor Binding 
and Cellular Uptake of Phage Display Derived Peptides. The fluorescent dyes used 
were: [Hoechst-BLUE for Nucleus, Alexa488-GREEN for actin, 2⁰(GAM/Cy3-RED) - 
1⁰(anti-M13) for Phage Peptides]. Areas of location overlap are indicated by YELLOW 
(Membrane) and PURPLE (Nucleus). 
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Figure 17. The Effect of Phage Peptide Incubation and Length of Initial Growth 
Cycle (24 hrs) on the Viability of U87-MG Cells. The populations consisted of 1 well 
each containing 100,000 cells. Cells were grown for 24 hrs and then incubated in a 10% 
phage/PBS (1X) for another 48 hrs. Standard well received only media and PBS well 
received PBS (1X) instead of phage peptide. Live/Dead staining was performed with 
Trypan Blue and no statistical difference in viability was observed (α = 0.05). 
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Figure 18. The Effect of Phage Peptide Incubation and Length of Initial Growth 
Cycle (48 hrs) on the Viability of U87-MG Cells. The populations consisted of 4 wells 
each containing 84,000 cells. Cells were grown for 48 hrs and then incubated in a 10% 
phage/PBS (1X) solution for another 48 hrs. Standard well received only media and PBS 
well received PBS (1X) instead of phage peptide. Live/Dead staining was performed with 
Trypan Blue and no statistical difference in viability was observed (α = 0.05). 
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Figure 19. The Effect of Phage Peptide Incubation on the Cell Proliferation of U87-
MG Cells. The populations consisted of 6 wells each containing 25,000 cells. Cells were 
grown for 48 hrs and then incubated in a 10% phage/BSA (0.5%) solution for another 48 
hrs. Standard well received only media and BSA well received BSA (0.5%) instead of 
phage peptide. An MTT assay was performed and no statistical difference in viability was 
observed (α = 0.05). 
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Figure 20. Whole-Cell ELISA Confirmation of U87-MG Cell Membrane Binding by 
Phage Peptides Using an HRP Conjugated Anti-M13 Antibody with a TMB 
Substrate and STOP-450 Solution. The populations consisted of 6 wells each 
containing 25,000 cells. Cells were grown for 48 hrs at 37⁰C and then incubated in a 10% 
phage/BSA (0.5%) solution for 2 hrs at 4⁰C. All phage peptide results were statistically 
significant compared to the no-phage negative control (α = 0.05). 
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Figure 21A. U87-MG Cells - Confirmation of Co-Localization and Cellular Uptake 
of Phage Display Derived Peptides and the Known ACKR3/CXCR7 Antibody, Anti-
RDC1. The fluorescent dyes used were: [Hoechst-BLUE for Nucleus, 2⁰(GAR/Cy3-
RED) - 1⁰(anti-RDC1) for ACKR3/CXCR7 receptor, 2⁰(DAM/Alexa488-GREEN) - 
1⁰(anti-M13) for Phage Peptides]. The areas of colocalization at the extracellular 
membrane and in the cytoplasm are indicated by the YELLOW overlap (RDC1-RED + 
Phage Peptide-GREEN). Areas of intracellular colocalization in and around the nucleus 
are indicated by the (Phage Peptide-GREEN + Nucleus-BLUE) overlap. 
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Figure 21B. U87-MG Cells - Confirmation of Co-Localization and Cellular Uptake 
of Phage Display Derived Peptides and the Known ACKR3/CXCR7 Antibody, Anti-
RDC1. The fluorescent dyes used were: [Hoechst-BLUE for Nucleus, 2⁰(GAR/Cy3-
RED) - 1⁰(anti-RDC1) for ACKR3/CXCR7 receptor, 2⁰(DAM/Alexa488-GREEN) - 
1⁰(anti-M13) for Phage Peptides]. The areas of colocalization at the extracellular 
membrane and in the cytoplasm are indicated by the YELLOW overlap (RDC1-RED + 
Phage Peptide-GREEN). Areas of intracellular colocalization in and around the nucleus 
are indicated by the (Phage Peptide-GREEN + Nucleus-BLUE) overlap. 
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Figure 22. Quantifying the Level of ACKR3/CXCR7 Activation Using a PathHunter 
β-Arrestin Assay (DiscoverX) with the Phage Peptides, the Endogenous Ligand 
SDF1α, and CHO-K1 Modified Cells. A 12-point dose response curve was performed 
according to the manufacturer’s instructions. The Phage Peptides showed no effect 
compared to SDF1α.   
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APPENDIX A 
 
3D MOLECULAR MODELS OF THE LIPOSOME COMPONENTS (C-70 
DERIVATIVE (ALM) AND EGG-PC) IN THIN-TUBE MODE AND CPK COLOR 
SCHEME 
 
 
The C-70 fullerene model measured ~8.0Å long by ~6.5Å wide. This 
measurement is consistent with the elongated structure of C-70 fullerenes relative to the 
spherical shapes of C-60 fullerenes. The assembled ALM model measured ~20Å long by 
6.5Å wide as was similar in size to the egg-PC model that measured 19.7Å long by 5.5Å 
wide.  
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APPENDIX B 
 
ALTERNATE VIEW OF THE 3D MOLECULAR MODELS OF THE LIPOSOME 
COMPONENTS IN APPENDIX A (C-70 DERIVATIVE (ALM) AND EGG-PC) IN 
SPACE-FILL MODE AND CPK COLOR SCHEME 
 
 
The C-70 fullerene model measured ~8.0Å long by ~6.5Å wide. This 
measurement is consistent with the elongated structure of C-70 fullerenes relative to the 
spherical shapes of C-60 fullerenes. The assembled ALM model measured ~20Å long by 
6.5Å wide as was similar in size to the egg-PC model that measured 19.7Å long by 5.5Å 
wide. 
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APPENDIX C 
 
3D MOLECULAR MODELS OF THE LIPOSOME COMPONENTS IN 
APPENDIX A AND THE SELECTED PHAGE PEPTIDE SEQUENCES (P-3, P-9, 
AND P-20) IN THIN-TUBE MODE AND CPK COLOR SCHEME 
 
 
The P-3 model measured ~28.5Å long by ~12.00Å wide. The P-9 model 
measured ~32.0Å long by ~10.00Å wide. The P-20 model measured ~27.5Å long by 
~6.5Å wide. These measurements were similar to the ones observed for the assembled 
ALM model and the egg-PC model as seen in Appendix A. 
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APPENDIX D 
 
3D MOLECULAR MODELS OF THE LIPOSOME COMPONENTS IN 
APPENDIX A AND THE SELECTED PHAGE PEPTIDE SEQUENCES (P-3, P-9, 
AND P-20) IN APPENDIX C IN SPACE-FILL MODE AND CPK COLOR 
SCHEME 
 
 
The P-3 model measured ~28.5Å long by ~12.00Å wide. The P-9 model 
measured ~32.0Å long by ~10.00Å wide. The P-20 model measured ~27.5Å long by 
~6.5Å wide. These measurements were similar to the ones observed for the assembled 
ALM model and the egg-PC model as seen in Appendix A. 
 
 
